jain.com
Public record. We host this document directly; the copy served here does not depend on any third party. Retrieved November 16, 2026.
Read the documentAlso at archive.org ↗

Skrypski v. Sampson — Entry #79: Defendants ANSWER to 54 Amended Complaint by Barbara K

Case: Skrypski v. Sampson cod · 1:25-cv-00306

filed January 29, 2025

What this document is

Docket entry #79 · filed October 05, 2026

Defendants ANSWER to 54 Amended Complaint by Barbara K. Gutierrez, L. Heath Sampson, Kenneth Shepard.(Loseman, Monica) (Entered: 10/05/2026)

Who is involved

Why we have it

We follow this case because it names a company we track, although that company is not a party:

A free copy from the RECAP archive of federal court filings (mirrored at the Internet Archive), retrieved November 16, 2026. Federal court filings are public records.

URL
https://archive.org/download/gov.uscourts.cod.240886/gov.uscourts.cod.240886.79.0.pdf
Kind
court_filing
Publisher
RECAP
Published
2026-11-11 00:00:00-05:00
Retrieved
2026-11-16 16:46:13.260357-05:00
HTTP status
200
MIME
application/pdf
Bytes
2207071
SHA-256
fec7aefd4fdf77bcd0be0f27f612ef9aba56d704d23b62fbfbeb9bf079ae1144

Document text

269 page(s), 628,868 characters, converted from the PDF's text layer · plain text.

Full text
Case No. 1:25-cv-00306-GPG-KAS         Document 79   filed 10/05/26   USDC Colorado
                                        pg 1 of 269


                          UNITED STATES DISTRICT COURT
                          FOR THE DISTRICT OF COLORADO
Civil Action No. 1:25-cv-00306-GPG-KAS

CHRISTOPHER SKRYPSKI, individually
and on Behalf of All Others Similarly Situated,
              Plaintiff,
v.
L. HEATH SAMPSON, KENNETH
SHEPARD, and BARBARA K.
GUTIERREZ,
              Defendants.

  DEFENDANTS’ ANSWER TO THE AMENDED CLASS ACTION COMPLAINT FOR
        VIOLATIONS OF THE FEDERAL SECURITIES LAWS (DKT. 54)


Case No. 1:25-cv-00306-GPG-KAS         Document 79       filed 10/05/26   USDC Colorado
                                       pg 2 of 269


       Defendants L. Heath Sampson, Kenneth Shepard, and Barbara K. Gutierrez

(collectively, “Defendants”) submit this Answer to Plaintiff Christopher Skrypski’s

Amended Class Action Complaint for Violations of the Federal Securities Laws (the

“Amended Complaint”; Dkt. 54), filed on January 9, 2026.

       The Court’s August 7, 2026 Order only addressed and allowed Plaintiff’s claims to

proceed with respect to the risk factor allegations found in Paragraphs 169–173, 177–

180, 184, 225, 244, and 278–281.* Defendants are not required to respond to allegations

that the Court has not determined are adequately alleged under the Private Securities

Litigation Reform Act of 1995, Abdo v. United States, 2024 WL 6473903, at *2 (D. Colo.

Dec. 5, 2024) (citing Nat’l Credit Union Admin. Bd. v. RBS Sec., Inc., 2013 WL 11332740,

at *5 (D. Kan. Oct. 24, 2013)), and, on that basis, deny those allegations. Except as

otherwise expressly stated herein, Defendants deny each and every claim, theory, and

allegation asserted in the Amended Complaint, and specifically deny liability under § 10(b)

and § 20(a) of the Securities Exchange Act of 1934 and U.S. Securities and Exchange

Commission (“SEC”) Rule 10b-5 promulgated thereunder. Pursuant to Rule 8(b)(6) of the

Federal Rules of Civil Procedure, averments in the Amended Complaint to which no

responsive pleading is required shall be deemed denied. Defendants expressly reserve

the right to amend and/or supplement this Answer as may be necessary.


*
 Defendants understand that Plaintiff disagrees with this interpretation of the Court’s
August 7, 2026 Order. Defendants have filed a motion seeking clarification of the Court’s
Order. See Dkt. 74. Should answers to these allegations be required, Defendants have
provided them below. Defendants will also amend this Answer if the Court’s order on their
Motion for Clarification renders it necessary.

                                            2


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                       pg 3 of 269


RESPONSE TO HEADINGS AND FOOTNOTES

      The Amended Complaint contains several headings, which Defendants have

included in this Answer. The headings are not properly pleaded allegations requiring a

response, and Defendants do not adopt the characterizations set forth in those headings.

To the extent any headings contain allegations requiring a response, Defendants deny

the allegations set forth therein. Defendants also deny the allegations contained in the

footnotes from Lead Plaintiff’s Amended Complaint, except where they explicitly note

otherwise.

      In answer to the Amended Complaint, Defendants state as follows:

RESPONSE TO INDIVIDUAL PARAGRAPHS IN THE AMENDED COMPLAINT

1. Lead Plaintiff Christopher Skrypski (“Lead Plaintiff” or “Plaintiff”) brings this class
   action against Defendants (defined below) pursuant Sections 10(b) and 20(a) of the
   Securities Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78j(b) and 78t(a)
   and Rule 10b-5, 17 C.F.R. § 240.10b-5, promulgated thereunder by the U.S.
   Securities and Exchange Commission (“SEC”), individually and on behalf of himself
   and all persons and entities similarly situated who purchased or otherwise acquired
   ModivCare Inc. (“ModivCare” or the “Company”) securities between November 3,
   2022 to September 15, 2024, inclusive (the “Class Period”).
      ANSWER: Paragraph 1 states a legal conclusion to which no response from

Defendants is required. To the extent a response is required, Defendants admit that the

Court appointed Christopher Skrypski as Lead Plaintiff. Defendants further admit that this

is a putative class action lawsuit purporting to bring claims against L. Heath Sampson,

Barbara K. Gutierrez, and Kenneth Shepard under Sections 10(b) and 20(a) of the

Exchange Act and Rule 10b-5 promulgated thereunder. Except as expressly admitted,

Defendants deny the allegations in Paragraph 1.


                                            3


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                        pg 4 of 269


2. Plaintiff alleges the following based upon personal knowledge as to himself and his
   own acts, and upon information and belief as to all other matters. Plaintiff’s information
   and belief is based on the investigation of his undersigned attorneys (“Lead Counsel”),
   which included, among other things, review and analysis of: (i) public documents,
   public filings, and wire and press releases published by and regarding ModivCare; (ii)
   Defendants’ other public statements, including transcripts of interviews Defendants
   participated in; (iii) interviews with individuals who are former employees of ModivCare;
   (iv) reports of securities and financial analysts, news articles, and other commentary
   and analysis concerning ModivCare and the industry in which the Company operates;
   and (v) pertinent court filings.
       ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations regarding Plaintiff’s purported investigation described in

Paragraph 2, and deny them on that basis. Defendants further deny that any alleged

statement, knowledge, conduct, document, or omission allegedly attributable to one

defendant is attributable to another.

3. Lead Counsel’s investigation into the matters alleged herein is continuing, and many
   relevant facts are known only to, or are exclusively within, the custody or control of
   Defendants. Plaintiff believes that substantial additional evidentiary support will exist
   for the allegations set forth herein after a reasonable opportunity for discovery.
       ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations regarding Lead Counsel’s investigation and “beliefs”

described in Paragraph 3, and deny them on that basis.

I.     NATURE OF THE ACTION

4. Plaintiff brings this securities fraud class action alleging that, throughout the Class
   Period, ModivCare’s Chief Executive Officer (“CEO”) L. Heath Sampson (“Sampson”),
   the Company’s Chief Financial Officer (“CFO”) Barbara Guiterrez (“Guiterrez”), and
   the CFO for the Company’s core non-emergency medical transport (“NEMT”)
   business Kenneth Shepard (“Shepard”) knowingly or severely recklessly made
   material misrepresentations to investors concerning the Company’s shared risk
   capitated contracts’ ability to offset ModivCare’s increased transportation costs from


                                             4


Case No. 1:25-cv-00306-GPG-KAS         Document 79       filed 10/05/26   USDC Colorado
                                       pg 5 of 269


   higher NEMT utilization by members. Defendants likewise made material
   misrepresentations that overstated the quality of ModivCare’s NEMT services and
   their cost-effectiveness for the Company, including with respect to a “multi-modal
   strategic initiative” that was intended to diversify the transportation methods available
   to members.
      ANSWER: Paragraph 4 states legal conclusions to which no response from

Defendants is required. Defendants also need not respond to the allegations in Paragraph

4 to the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-

K and 10-Q risk disclosures, which are the only alleged misstatements that the Court

addressed in its August 7, 2026 Order (see Dkt. 67 at 5; see also Dkt. 74 at 2–3), and

Defendants deny them on that basis. Defendants deny that any alleged statement,

knowledge, conduct, document, or omission allegedly attributable to one defendant is

attributable to another. To the extent a response is required, Defendants admit that Heath

Sampson served as ModivCare’s Chief Executive Officer, that Barbara Gutierrez served

as ModivCare’s Chief Financial Officer beginning September 18, 2023, and that Kenneth

Shepard served as Chief Financial Officer of ModivCare’s NEMT segment. Except as

expressly admitted, Defendants deny the allegations in Paragraph 4.

5. ModivCare is a healthcare services company whose core business entails
   coordinating and managing non-emergency medical transportation in the United
   States for individuals who ModivCare refers to as “members.” The Company is paid
   primarily by its members’ insurers, which ModivCare calls “payors” and who are state
   Medicaid programs and managed care organizations (“MCOs”).
      ANSWER: Defendants admit that ModivCare is a healthcare services company

that provides non-emergency medical transportation (“NEMT”) services; that the

individuals who use ModivCare’s services are referred to as “members”; and that

ModivCare is paid by “payors” that include private healthcare insurers, state Medicaid


                                             5


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                        pg 6 of 269


programs, and managed care organizations. Except as expressly admitted, Defendants

deny the allegations in Paragraph 5.

6. During the COVID-19 pandemic, ModivCare’s members utilized fewer NEMT services
   due to stay at home orders and a rise in telehealth. Despite this drop-off in utilization
   (i.e., the rate at which ModivCare’s members use its NEMT services), the Company’s
   profits soared as a result of how its contracts with payors were structured. Namely,
   ModivCare’s contracts were predominantly full-risk capitated contracts that provided
   the Company with a fixed per-member per-month (“PMPM”) fee for each of the payors’
   eligible members irrespective of whether those members were utilizing the Company’s
   services.
       ANSWER: Defendants admit that, during the COVID-19 pandemic, ModivCare’s

members utilized fewer NEMT services due to stay at home orders and a rise in telehealth.

Defendants further admit that, both before, during, and after the COVID-19 pandemic,

ModivCare had full-risk capitated contracts that provided that payors pay a fixed amount

per member per month, and ModivCare assumes the responsibility of meeting the

covered healthcare-related transportation requirements for the eligible members in the

customer’s program, regardless of how many or how few times the member utilizes

ModivCare’s services (usage) or how much cost is incurred in providing those services

(fulfillment costs). Except as expressly admitted, Defendants deny the allegations in

Paragraph 6.

7. Given that under the full-risk contracts ModivCare would receive the same PMPM if
   the Company was experiencing a surge in utilization from members (which had the
   effect of reducing the profit margin considerably as transportation costs increased),
   the Company began renegotiating to shift its full-risk contracts to shared risk contracts
   as pandemic restrictions eased and ModivCare anticipated that payors’ members
   would begin to increase their use of the Company’s NEMT services.


                                             6


Case No. 1:25-cv-00306-GPG-KAS         Document 79       filed 10/05/26   USDC Colorado
                                       pg 7 of 269


       ANSWER: Defendants admit and allege that, after the COVID-19 pandemic,

ModivCare anticipated that utilization and costs for providing NEMT services would

increase. Defendants further admit that ModivCare and certain payors renegotiated

certain contracts from full-risk capitated contracts to shared-risk capitated contracts.

Except as expressly admitted, Defendants deny the allegations in Paragraph 7.

8. ModivCare claimed that, under the shared risk contracts, the Company’s PMPM would
   be adjusted upward or downward (depending on the actual realized transportation
   volumes or costs). The purpose of these adjustments was to purportedly guarantee
   that the Company would earn a certain profit level regardless of how much payors’
   members were using the services or how much transportation costs increased.
   Conversely, ModivCare’s profits were also capped under these shared risk contracts,
   meaning if the Company reached the profit threshold, it would rebate its payors for
   such overages.
       ANSWER: Defendants admit that certain shared-risk contracts include provisions

for reconciliations, risk corridors, and/or profit rebates, which allow for periodic

reconciliations between ModivCare and the payors based on actual costs and/or trip

volumes and may result in refunds to the payor (contract payables) if utilization and costs

are low, or additional payments due from the payor (contract receivables) if utilization or

costs are high. To the extent that Paragraph 8 characterizes or quotes from ModivCare’s

public filings, Defendants respectfully refer the Court to the complete documents, which

speak for themselves, and deny any allegations inconsistent therewith. Except as

expressly admitted, Defendants deny the allegations in Paragraph 8.

9. Thus, during the adjustment process for shared risk contracts, ModivCare determined
   whether the profit threshold had been met or exceeded. If the profit threshold had not
   been met, then the Company would generally record an asset (i.e., contract receivable)
   for which it would seek additional payment from the payor. On the other hand, if the


                                            7


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26    USDC Colorado
                                        pg 8 of 269


   profit threshold was exceeded, then ModivCare would record a liability (i.e., contract
   payable) that would need to be paid to the payor.
       ANSWER: Defendants admit that accrued contract payables primarily represent

overpayments and liability reserves on certain risk corridor, profit rebate and reconciliation

contracts, and contract receivables primarily represent underpayments and receivables

on certain risk corridor, profit rebate, and reconciliation contracts. Except as expressly

admitted, Defendants deny the allegations in Paragraph 9.

10. Throughout the Class Period, which begins on November 3, 2022, Sampson
    relentlessly touted the shared risk contracts’ purported benefits for ModivCare and its
    customers. Indeed, Sampson assured investors that, “because of” ModivCare’s
    shared risk “contracts, we’re able to pass [increased transportation costs]
    through to a lot of our customers” and further claimed “if utilization goes way up,
    we’re going to share in that. If costs go up, we’re going to share in that. And
    that’s the way these contracts work.” Sampson further vowed that ModivCare was
    “going to get paid on” instances where “utilization is going up and we’re doing
    more trips and... it’s more expensive to us[.]” Indeed, Sampson assured “it gets
    put on the balance sheet, and then we’ll collect it over the next 3 to 6 months.”
    As such, Sampson represented that ModivCare’s shared risk contracts were
    “structured so we have a win-win[.]”
       ANSWER: Defendants need not respond to the allegations in Paragraph 10 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. Paragraph 10 also states legal conclusions to which no response

from Defendants is required. To the extent a response is required, Paragraph 10

characterizes or quotes from ModivCare’s November 3, 2022 earnings call and Deutsche

Bank’s 31st Annual Leveraged Finance Conference on October 3, 2023. Defendants


                                              8


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                        pg 9 of 269


respectfully refer the Court to the complete recordings from those events, which speak

for themselves, and deny any allegations inconsistent therewith. Defendants otherwise

deny the allegations in Paragraph 10.

11. Defendant Sampson repeated this mantra on at least 15 occasions during the Class
    Period, and detailed exactly what “win-win” meant (i.e., ModivCare would “share in []
    increased [transportation] costs” which would thereby “allow[] [the Company] to
    really have stable rigid margins regardless of utilization and cost[,]” “add[] [an]
    additional layer of predictability to [its] cash flow[,]” and create “more normalized
    working capital[.]”).
       ANSWER: Defendants need not respond to the allegations in Paragraph 11 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. Paragraph 11 also states legal conclusions to which no response

from Defendants is required. To the extent a response is required, Paragraph 11

characterizes or quotes from Defendant’s public statements, and Defendants respectfully

refer the Court to the complete recordings from those events, which speak for themselves,

and deny any allegations inconsistent therewith. Defendants otherwise deny the

allegations in Paragraph 11.

12. In addition, every quarterly report filed with the SEC on behalf of ModivCare, falsely
    represented that “[t]here have been no material changes” to the Company’s
    previously issued risk factors in addition to containing purported risk disclosures that
    speculatively cautioned that, inter alia, “implementation of alternative payment
    models[,]” changes in payment levels from ... third-party payors[,]” and “[d]elays
    in collection, or non-collection, of our accounts receivable” “could adversely
    affect” revenues[,]” “operations[,]” or “financial condition[.]”


                                             9


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26   USDC Colorado
                                       pg 10 of 269


      ANSWER: Defendants need not respond to the allegations in Paragraph 12 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 12 characterizes

or quotes from ModivCare’s Forms 10-Q or 10-K, and Defendants respectfully refer the

Court to the complete documents, which speak for themselves, and deny any allegations

inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 12.

13. In reality, unbeknownst to investors, ModivCare’s true-up process under the shared
    risk contracts persistently caused disputes with customers. For instance, CW2,
    ModivCare’s Vice President (“VP”) of Transportation, confirmed that mismatches
    between ModivCare’s internal utilization data and payors’ actual “encounter data”
    caused payors to contend that they owed ModivCare far less than the Company
    claimed. Rather than sharing in higher costs as Defendants’ claimed, ModivCare was
    locked in disputes about how many trips members actually took, which had a
    significant financial impact. Indeed, CW2 explained that such utilization discrepancies
    could result in PMPM rates fluctuating $3 or more and would be multiplied across large
    membership populations. According to CW2, ModivCare was subjected to monthly
    liquidated damages for rejected encounter data and routinely forced to accept partial
    payments as settlements as a result of the encounter related true-up disputes.
      ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the confidential witness (“CW”) allegations in Paragraph 13 and deny them

on that basis. Defendants further deny that any alleged statement, knowledge, conduct,

document, or omission allegedly attributable to one defendant is attributable to another.

Defendants otherwise deny the allegations in Paragraph 13.

14. CW3 likewise stated that ModivCare faced significant disputes over risk corridors and
    profits. CW3 provided an example where New Jersey—one of the Company’s largest
    contracts—asserted that ModivCare had exceeded its profit cap and sought


                                            10


Case No. 1:25-cv-00306-GPG-KAS         Document 79     filed 10/05/26   USDC Colorado
                                      pg 11 of 269


   repayment. CW3 confirmed that ModivCare was required to return a portion of those
   profits to the state.
      ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the CW allegations in Paragraph 14 and deny them on that basis.

Defendants otherwise deny the allegations in Paragraph 14.

15. ModivCare not only experienced disputes with customers concerning what was owed
    to the Company under the shared risk contracts but also faced significant challenges
    collecting new monthly PMPM payments from payors that ModivCare was in arrears
    for as a result of previous utilization and mounting contract payables. For instance,
    CW2 confirmed that such payors withheld monthly payments to offset the balance that
    ModivCare owed to the payor. According to CW2, even where ModivCare conveyed
    that payors needed to continue making monthly payments, payors refused— resulting
    in disputes that dragged on for “a very long time.”
      ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the CW allegations in Paragraph 15 and deny them on that basis.

Defendants otherwise deny the allegations in Paragraph 15.

16. Despite ModivCare’s claims that its cash flow would become more normalized and
    predictable through the shared risk contracts, the Company faced a significant cash
    crunch. ModivCare’s working capital was affected by the rampant collectability issues
    stemming from its true-up disputes as well as “repayments” that ModivCare elected to
    make to payors who had paid hefty PMPMs during the Covid-19 pandemic despite
    members’ low utilization. Indeed, ModivCare was shelling out hundreds of millions of
    dollars in cash and drawing down on its revolving credit facility to pay down its
    contracts payables balance while simultaneously facing a mounting contracts
    receivables balance that was not coming in the door.
      ANSWER: To the extent Paragraph 16 characterizes or quotes from ModivCare’s

public statements and disclosures regarding its cash flow, working capital, contracts

receivables and contracts payables balances, Defendants respectfully refer the Court to

the complete statements and documents, which speak for themselves, and deny any


                                           11


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                      pg 12 of 269


allegations inconsistent therewith. Defendants otherwise deny the allegations in

Paragraph 16.

17. ModivCare’s collectability issues under the shared risk contracts were also
    exacerbated by payors who, dissatisfied with the Company’s service and
    technological shortcomings, placed the Company on performance improvement plans,
    delayed payments, sought monthly liquidated damages, and canceled contracts.
    Indeed, CWs confirmed that, prior to and continuing through the Class Period,
    ModivCare received increasing complaints about its NEMT service, including driver
    no shows and on-time performance issues, and about promised technological
    enhancements, aimed at reducing those very complaints, that ModivCare had not
    delivered.
      ANSWER: Defendants need not respond to the allegations in Paragraph 17 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the allegations concerning

whether payors were “dissatisfied” with ModivCare and the CW allegations in Paragraph

17 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

17.

18. For instance, CW3 stated ModivCare consistently failed to provide payors with the
    technology and system maintenance offerings that the Company committed to
    delivering in contracts, including ride scheduling, real-time reporting, GPS tracking,
    and dynamic trip reassignment for medical appointments. As a result, according to
    CW3, missed appointments and no-shows were significant service issues that
    ModivCare had throughout CW3’s tenure that did not improve. CW3 further recalled
    that ModivCare consistently failed to meet key performance indicators (“KPIs”),
    including on-time performance, no vehicle available (“NVAs”) (which caused missed


                                           12


Case No. 1:25-cv-00306-GPG-KAS           Document 79      filed 10/05/26   USDC Colorado
                                        pg 13 of 269


      rides), and call center complaints regarding delayed call answer, which affected most
      payors.
         ANSWER: Defendants need not respond to the allegations in Paragraph 18 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

18 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

18.

19. CW3 also stated that ModivCare’s poor service delivery, long-standing weaknesses
    in technology, and reliance on an outdated platform caused major contracts to be
    under threat throughout September 2023 (i.e., the end of CW3’s tenure). Likewise,
    CW2 stated that, beginning around the second quarter of 2022 (“2Q2022”) and
    continuing throughout CW2’s tenure, ModivCare’s poor operational performance
    (such as call center failures) led to client dissatisfaction and monthly liquidated
    damages of hundreds of thousands of dollars. CW1 also stated that, during CW1’s
    last year with ModivCare, the Company began losing NEMT contracts because
    service levels “were way down” due to poor service quality and high employee
    turnover. Indeed, CW1 stated during this time, payors were “literally cancelling
    contracts because the service, and the people trying to perform the services, kept
    changing so much. The service levels were way down.”
         ANSWER: Defendants need not respond to the allegations in Paragraph 19 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge


                                             13


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 14 of 269


or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

19 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

19.

20. Customers were also dissatisfied with ModivCare’s multi-modal strategic initiative,
    which was intended to reduce transportation costs and offset the impacts of increased
    utilization. CWs confirmed that ModivCare’s multi-modal strategic initiative was
    disliked by users and as a result, “fared very poorly” and failed to achieve forecasted
    cost savings.
       ANSWER: Defendants need not respond to the allegations in Paragraph 20 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the allegations concerning

unidentified “customers.” Defendants further lack knowledge or information sufficient to

form a belief as to the truth of the CW allegations in Paragraph 20 and deny them on that

basis. Defendants otherwise deny the allegations in Paragraph 20.

21. Nevertheless, Defendant Sampson professed that ModivCare was “meeting or
    exceeding all [its] customers’ quality and service level requirements[,]” including “on-
    time performance and reduced miss trips[,]” and touted that “[o]ur multimodal
    transportation partnership strategy has led to increased customer satisfaction and
    reduced costs.”
       ANSWER: Defendants need not respond to the allegations in Paragraph 21 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;


                                             14


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                       pg 15 of 269


see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 21 characterizes

or quotes from ModivCare’s August 4, 2023 earnings call, and Defendants respectfully

refer the Court to the complete recording from that earnings call, which speaks for itself,

and deny any allegations inconsistent therewith. Defendants otherwise deny the

allegations in Paragraph 21.

22. Importantly, Defendants knew or recklessly disregarded that payors were dissatisfied
    with ModivCare’s NEMT services and technological shortcomings, as well as the
    shared risk contract disputes. For instance, during a May 2023 Summit, CW3
    presented competitive analyses that showed, inter alia, long-standing weaknesses in
    technology and poor service delivery, to Sampson and others in leadership. Likewise,
    between March and May of 2023 and continuing throughout the Class Period,
    Defendant Shepard (who was Defendant Sampson’s direct report) participated in
    customer dispute calls regarding the shared risk contract that had escalated to a point
    where such customers requested Shepard’s involvement. CWs also confirmed that
    Defendants Sampson and Shepard attended regular meetings where rising service
    complaints, contract de-implementations, missed KPIs, and results of the strategic
    initiatives were discussed in detail, and received presentations regarding de-
    implementations (which Defendants could also access “whenever they wanted”).
    Defendants also admittedly monitored NEMT service data and regularly reported on
    such information and the shared risk contracts in detail during public earnings calls
    with investors. Moreover, as a result of his admittedly close relationships and frequent
    discussions with payors’ executives regarding contracting and repricing, Sampson
    also knew that payors were dissatisfied with ModivCare’s service levels and
    technology offerings, were refusing to pay, delaying payments, and seeking liquidated
    damages, refusing to share in increased costs under the shared risk contracts, and
    cancelling contracts as a result of service and technology issues.
       ANSWER: Defendants need not respond to the allegations in Paragraph 22 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 22 states legal


                                            15


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                       pg 16 of 269


conclusions to which no response is required. Defendants further lack knowledge or

information sufficient to form a belief as to the truth of the allegations concerning

unidentified “payors” and the CW allegations in Paragraph 22 and deny them on that

basis. Defendants further deny that any alleged statement, knowledge, conduct,

document, or omission allegedly attributable to one defendant is attributable to another.

Defendants otherwise deny the allegations in Paragraph 22.

23. The truth about ModivCare’s shared risk contracts and NEMT services issues was
    gradually revealed to investors through a series of partial disclosures during the Class
    Period, often as Defendants continued to simultaneously mislead investors. First, on
    May 4, 2023, Defendants Sampson and Shepard revealed that ModivCare had a net
    loss of $4.0 million for the first quarter of 2023 and had expended nearly $3 million in
    cash as a result of a $7 million reduction in contract payables and $31 million increase
    in contract receivables during the quarter. On this news, ModivCare’s common stock
    price fell sharply, declining $11.30 per share, or approximately 16%, from $69.30 per
    share on May 3, 2023 to $58.00 per share on May 4, 2023.
       ANSWER: Paragraph 23 states legal conclusions to which no response is required.

To the extent a response is required, Defendants admit and allege that ModivCare’s

earnings and stock prices at various times are matters of public record and deny any

allegations inconsistent therewith. Paragraph 23 also characterizes or quotes from

ModivCare’s May 4, 2023 press release and earnings call. Defendants respectfully refer

the Court to the complete document or recording thereof, which speak for themselves,

and deny any allegations inconsistent therewith. Defendants further deny that any alleged

statement, knowledge, conduct, document, or omission allegedly attributable to one

defendant is attributable to another. Except as expressly admitted, Defendants deny the

allegations in Paragraph 23.


                                            16


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                       pg 17 of 269


24. Next, on August 3, 2023 while reporting second quarter 2023 financials, ModivCare
    slashed 2023 full-year Adjusted Earnings Before Interest, Taxes, Depreciation, and
    Amortization (“EBITDA”) guidance due to, inter alia, “increased utilization and related
    higher call volumes in NEMT,” and disclosed that the Company had used $108.2
    million in cash and drew $126.5 million on its revolving credit facility due to “a
    temporary timing mismatch between [NEMT] payments and collections” and $65
    million in accelerated payments made to “a few large state clients” that “occurred
    earlier than anticipated[.]” In response to this news, ModivCare’s common stock price
    declined $2.86, or approximately 7%, from $38.24 per share on August 3, 2023, to
    close at $35.38 per share on August 4, 2023.
       ANSWER: Paragraph 24 states legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants admit and allege

that ModivCare’s stock price at various times is a matter of public record and deny any

allegations inconsistent therewith. Paragraph 24 also characterizes or quotes from

ModivCare’s August 3, 2023 press release. Defendants respectfully refer the Court to the

complete document, which speaks for itself, and deny any allegations inconsistent

therewith. Except as expressly admitted, Defendants deny the allegations in Paragraph

24.

25. Then, on February 22, 2024, after the market closed, Defendants disclosed that
    ModivCare’s free cash flow for fourth quarter 2023 and full year 2023 were negative
    $36.8 million and negative $125.3 million, respectively, and the Company had drawn
    $113.8 million from its revolving credit facility. ModivCare’s dismal financials stemmed
    from NEMT “margin pressure” related to several contract losses, “sooner than
    anticipated, large COVID-related working capital needs[,]” and a ~$35.9 million
    delayed payment from a client. On this news, ModivCare’s common stock price fell
    $17.25 per share, or approximately 39%, from a close of $43.87 on February 22, 2024
    to a close of $26.62 on February 23, 2024 on heavy trading volume.
       ANSWER: Paragraph 25 states legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants admit and allege

that ModivCare’s stock price at various times is a matter of public record and deny any


                                            17


Case No. 1:25-cv-00306-GPG-KAS           Document 79       filed 10/05/26    USDC Colorado
                                        pg 18 of 269


allegations inconsistent therewith. Paragraph 25 also characterizes or quotes from

ModivCare’s February 22, 2024 press release and Form 8-K. Defendants respectfully

refer the Court to the complete documents, which speak for themselves, and deny any

allegations inconsistent therewith. Defendants further deny that any alleged statement,

knowledge, conduct, document, or omission allegedly attributable to one defendant is

attributable to another. Except as expressly admitted, Defendants deny the allegations in

Paragraph 25.

26. Analysts were caught off guard by Defendants’ contract loss disclosures. For instance,
    in two reports issued on February 23, 2024 Deutsche Bank initially noted that the
    “contract losses in NEMT” as “new information” while the later report noted that it was
    “[m]ake or break time” for the Company. The analyst also stated in the first report that
    “[w]ith several bumps on the road over the past year and struggles with FCF
    generation, we are unable to continue recommending MODV and downgrade to a
    Hold.” In the second report, the analyst added the “[m]ismatch between receivables
    and payables has been a persistent cash flow headwind for MODV over the last year”
    and the “lack of visibility into quarter to quarter performance of the shared risk contract
    book and the aggressive operating leverage implied in the 2H quarters is likely to
    result in investors taking a wait-and-see approach.”
       ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning the reaction of unidentified analysts in Paragraph

26 and deny them on that basis. Paragraph 26 characterizes or quotes from a Deutsche

Bank analyst report dated February 23, 2024, and Defendants respectfully refer the Court

to the complete document, which speaks for itself, and deny any allegations inconsistent

therewith. Defendants otherwise deny the allegations in Paragraph 26.

27. Nevertheless, even as late as August 8, 2024, when Defendants were already
    renegotiating prepayment terms with its shared risk NEMT customers in an desperate
    effort to bring cash in the door, Defendants Sampson and Guiterrez assured investors
    that ModivCare’s shared risk contracts were “win-win ... from a margin and P&L


                                              18


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                       pg 19 of 269


   perspective[,]” and “working as designed and protecting the downside [risk] and
   protecting the P&L[.]”
       ANSWER: Defendants need not respond to the allegations in Paragraph 27 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Paragraph 27 characterizes

or quotes from ModivCare’s August 8, 2024 earnings call, and Defendants respectfully

refer the Court to the complete recording, which speaks for itself, and deny any allegations

inconsistent therewith. Defendants further deny that any alleged statement, knowledge,

conduct, document, or omission allegedly attributable to one defendant is attributable to

another. Defendants otherwise deny the allegations in Paragraph 27.

28. Only one month later, on September 12, 2024, contrary to Defendants’ misstatements
    during the Class Period, Defendants revealed that “the Company has not offset the
    existing and continued accumulation of receivables during the period” and though
    “collection and mitigation efforts continue, there remains the possibility that the
    Company will not achieve full resolution in a timely manner or at all if unforeseen
    circumstances arise.” The Company’s further revealed that its annual report for the
    year ended December 31, 2023, which was filed with the SEC on Form 10-K on
    February 26, 2024 (“FY2023 10K”), was updated to reflect a “going concern.” In
    response to this news, ModivCare’s common stock price declined $18.43, or
    approximately 59%, from $31.19 per share on September 11, 2024 to $12.76 per
    share on September 12, 2024 on heavy trading volume.
       ANSWER: Paragraph 28 states legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants admit and allege

that ModivCare’s stock price at various times is a matter of public record and deny any

allegations inconsistent therewith. Paragraph 28 also characterizes or quotes from


                                            19


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                      pg 20 of 269


ModivCare’s September 12, 2024 Form 8-K. Defendants respectfully refer the Court to

the complete document, which speaks for itself, and deny any allegations inconsistent

therewith. Defendants further deny that any alleged statement, knowledge, conduct,

document, or omission allegedly attributable to one defendant is attributable to another.

Except as expressly admitted, Defendants deny the allegations in Paragraph 28.

29. Then, on September 16, 2024, Defendants revealed that ModivCare had “experienced
    delays in the timely collection of approximately $60 million of its outstanding $159.3
    million in NEMT segment current contract receivables, primarily from MCO customers,
    as of June 30, 2024” (i.e., over a month before Defendants’ August 8, 2024
    misstatements) and Defendants also slashed the Company’s 2024 Adjusted EBITDA
    guidance range “primarily due to NEMT segment pricing accommodations made to
    strategically retain and expand key customer relationships.” In response, ModivCare’s
    common stock price fell $1.40, or nearly 10%, from a close of $14.12 per share on
    September 13, 2024 to a close of $12.72 per share on September 16, 2024.
      ANSWER: Paragraph 29 states legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants admit and allege

that ModivCare’s stock price at various times is a matter of public record and deny any

allegations inconsistent therewith. Paragraph 29 characterizes or quotes from

ModivCare’s September 16, 2024 Form 8-K. Defendants respectfully refer the Court to

the complete document, which speaks for itself, and deny any allegations inconsistent

therewith. Defendants further deny that any alleged statement, knowledge, conduct,

document, or omission allegedly attributable to one defendant is attributable to another.

Except as expressly admitted, Defendants deny the allegations in Paragraph 29.

30. Analysts were shocked, particularly given the Company’s previous reticence to
    provide details around the delayed payment dispute. For instance, a September 17,
    2024 Barrington Research reduced its price target by $16, expressly highlighted that
    the collectability concerns were “particularly troubling since the company had


                                           20


Case No. 1:25-cv-00306-GPG-KAS           Document 79      filed 10/05/26   USDC Colorado
                                        pg 21 of 269


   explicitly stated in prepared remarks on its Q2 conference call in early August that it
   had visibility into $60 million of near-term cash collections from a couple of its large
   customers.” The report added that such “commentary contributed materially to our
   decision to upgrade the shares six weeks ago and probably served as similar
   comfort to many investors.”
       ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning the reaction of unidentified analysts in Paragraph

30 and deny them on that basis. Paragraph 30 characterizes or quotes from a Barrington

Research analyst report dated September 17, 2024, and Defendants respectfully refer

the Court to the complete document, which speaks for itself, and deny any allegations

inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 30.

31. Defendants would later admit after the Class Period on November 7, 2024, ModivCare
    planned to shift its shared risk contracts and the majority of the Company’s revenue
    to fee-for-service (“FFS”) arrangements because the shared risk contracts were not
    offering the Company or its customers a win-win but instead, because ModivCare had
    been paid lower under the shared risk contacts and the true-up “costs were higher
    than a lot of [ModivCare’s customers] expected[,]” “surprise[d] ... a lot of our payers”
    “[a]nd that was painful.”
       ANSWER: Paragraph 31 characterizes or quotes from ModivCare’s November 7,

2024 earnings call, and Defendants respectfully refer the Court to the complete recording,

which speaks for itself, and deny any allegations inconsistent therewith. Defendants

further deny that any alleged statement, knowledge, conduct, document, or omission

allegedly attributable to one defendant is attributable to another. Defendants otherwise

deny the allegations in Paragraph 31.

32. Defendants’ fraudulent and misleading statements served to artificially inflate the price
    of ModivCare’s common stock throughout the Class Period, causing massive investor
    losses when the price of the stock precipitously declined with each disclosure about


                                             21


Case No. 1:25-cv-00306-GPG-KAS           Document 79      filed 10/05/26    USDC Colorado
                                        pg 22 of 269


      ModivCare’s shared risk contracts and service issues. Lead Plaintiff hereby seeks
      damages individually and on behalf of the Class.
         ANSWER: Paragraph 32 states legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants deny the

allegations in Paragraph 32.

II.      JURISDICTION AND VENUE

33. The claims asserted herein arise under §§ 10(b) and 20(a) of the Exchange Act, 15
    U.S.C. § 78j(b) and § 78t(a), and Rule 10b-5 promulgated thereunder by the SEC, 17
    C.F.R. § 240.10b-5.
         ANSWER: Paragraph 33 states legal conclusions to which no response from

Defendants is required.

34. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1331
    and § 27 of the Exchange Act, 15 U.S.C. § 78aa.
         ANSWER: Paragraph 34 states legal conclusions to which no response from

Defendants is required.

35. This Court has jurisdiction over each Defendant named herein because each
    Defendant is an individual who has sufficient minimum contacts with this District to
    render the exercise of jurisdiction by the District Court permissible under traditional
    notions of fair play and substantial justice.
         ANSWER: Paragraph 35 states legal conclusions to which no response from

Defendants is required.

36. Venue is proper in this Court pursuant to 28 U.S.C. § 1391(b) and § 27 of the
    Exchange Act because many of the false and misleading statements were made in or
    issued from this District. ModivCare is headquartered in this District, with its principal
    place of business located at 6900 Layton Avenue, 12th Floor, Denver, Colorado 80237.
         ANSWER: Paragraph 36 states legal conclusions to which no response from

Defendants is required. To the extent that these allegations are deemed to be factual,


                                             22


Case No. 1:25-cv-00306-GPG-KAS           Document 79     filed 10/05/26   USDC Colorado
                                        pg 23 of 269


Defendants admit that ModivCare’s principal place of business was located at 6900 E

Layton Avenue, 12th Floor, Denver, Colorado 80237, and that venue is proper in this Court.

Except as expressly admitted, Defendants deny the allegations in Paragraph 36.

III.   PARTIES

       A.     Plaintiff

37. Court-appointed Lead Plaintiff Christopher Skrypski (“Lead Plaintiff” or “Plaintiff”)
    purchased ModivCare common stock during the Class Period, as set forth in his
    previously filed certification (ECF No. 17-1) and incorporated by reference herein, and
    suffered damages as set forth herein.
       ANSWER: Paragraph 37 states legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants admit that the

Court appointed Christopher Skrypski as Lead Plaintiff. Defendants lack knowledge or

information sufficient to form a belief as to the truth of the remaining allegations in

Paragraph 37 and deny them on that basis. Except as expressly admitted, Defendants

deny the allegations in Paragraph 37.

       B.    Defendants

38. At all relevant times, Defendant L. Heath Sampson served as ModivCare’s President
    and CEO as well as a Director on the Company’s Board of Directors (“Board”). Prior
    to his appointment to such positions, Sampson was ModivCare’s Interim CEO
    between August 1, 2022 and November 1, 2022 and its CFO between February 26,
    2021 and September 18, 2023. Defendant Barbara Gutierrez succeeded Sampson as
    ModivCare’s CFO. Sampson also led ModivCare’s Mobility (i.e., NEMT) business
    between January 2022 and April 12, 2022, when he was succeeded by Ilias Simpson
    as President of the Company’s Mobility division.
       ANSWER: Defendants admit that Mr. Sampson served as ModivCare’s President

and Chief Executive Officer and as a member of ModivCare’s Board of Directors during

the alleged Class Period; that Mr. Sampson previously served as ModivCare’s Interim


                                            23


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                       pg 24 of 269


Chief Executive Officer; and that Mr. Sampson served as ModivCare’s Chief Financial

Officer prior to and for part of the alleged Class Period. Defendants further admit that Mr.

Sampson previously led ModivCare’s Mobility division, and that he was succeeded by

Ilias Simpson as President of ModivCare’s Mobility division. Defendants also admit that

Ms. Gutierrez succeeded Mr. Sampson as Chief Financial Officer. Except as expressly

admitted, Defendants deny the allegations in Paragraph 38.

39. At all relevant times, Defendant Kenneth Shepard served as ModivCare’s CFO for the
    Company’s NEMT business.
       ANSWER: Defendants admit that Mr. Shepard served as Chief Financial Officer of

ModivCare’s NEMT segment during the alleged Class Period. Except as expressly

admitted, Defendants deny the allegations in Paragraph 39.

40. Defendant Barbara Gutierrez joined ModivCare on September 18, 2023 as the
    Company’s CFO and held this position throughout the remainder of the Class Period.
    On May 5, 2025, ModivCare announced Gutierrez’s employment was being
    terminated effective May 31, 2025.
       ANSWER: Defendants admit that Ms. Gutierrez was ModivCare’s Chief Financial

Officer from September 18, 2023 until May 31, 2025. Defendants further admit that, on

May 5, 2025, ModivCare filed a Form 8-K with the SEC announcing that Ms. Gutierrez

would depart the Company effective May 31, 2025. Except as expressly admitted,

Defendants deny the allegations in Paragraph 40.

41. Defendants Sampson, Shepard, and Gutierrez are collectively referred to herein as
    the “Defendants.”
       ANSWER: Paragraph 41 does not contain any factual allegations requiring a

response. To the extent a response is required, Defendants admit that the Amended

Complaint refers to Mr. Sampson, Mr. Shepard, and Ms. Gutierrez collectively as the


                                            24


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 25 of 269


“Defendants.” Except as expressly admitted, Defendants deny the allegations in

Paragraph 41.

42. The Defendants, by virtue of their high-level positions at ModivCare, directly
    participated in the management of ModivCare and were directly involved in the day-
    to-day operations of ModivCare at the highest levels. As such, they were privy to
    confidential, proprietary information concerning the Company and its business
    operations, growth, and financial condition. As set forth below, the materially misstated
    information conveyed to the public was the result of the individual and collective
    actions of these individuals.
       ANSWER: Paragraph 42 states legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants deny the

allegations in Paragraph 42.

43. As senior executives at a publicly held company with securities registered with the
    SEC and, throughout the Class Period, traded on the Nasdaq Global Select Market
    (“NASDAQ”), the Defendants each had a duty to disseminate prompt, accurate, and
    truthful information with respect to the Company’s business, operations, financial
    statements, and internal controls, and to correct any previously issued statements that
    were or had become materially misleading or untrue, so that the market price of
    ModivCare’s publicly traded securities would be based on accurate information. Each
    Defendant violated these requirements and obligations during the Class Period.
       ANSWER: Paragraph 43 contains legal conclusions to which no response from

Defendants is required. To the extent a response is required, Defendants admit that

ModivCare’s common stock was registered with the SEC and traded on the Nasdaq

Global Select Market during the alleged Class Period. Except as expressly admitted,

Defendants deny the allegations in Paragraph 43.

44. As a result of their positions of control and authority as senior executives, the
    Defendants were able to and did control the content of the public statements issued
    by the Company during the Class Period. Each Defendant had the ability to correct
    the statements or prevent them from being released into the public sphere.


                                             25


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26   USDC Colorado
                                       pg 26 of 269


   Accordingly, the Defendants are responsible for the accuracy of the materially false
   and misleading public statements detailed in this complaint.
      ANSWER: Paragraph 44 contains legal conclusions to which no response from

Defendants is required. Defendants deny that any alleged statement, knowledge, conduct,

document, or omission allegedly attributable to one defendant is attributable to another.

To the extent a response is required, Defendants deny the allegations in Paragraph 44.

45. As a result of their positions of control and authority as senior executives, the
    Defendants had access to adverse, undisclosed information about the Company’s
    business, operations, financial statements, and internal controls through their access
    to internal corporate documents and conversations with other corporate officers and
    employees. Defendants knew or recklessly disregarded that the positive
    representations they made about the Company were materially false and misleading
    and material facts omitted from positive representations made by Defendants about
    the Company rendered those representations materially false and misleading, as
    detailed herein.
      ANSWER: Paragraph 45 contains legal conclusions to which no response from

Defendants is required. Defendants deny that any alleged statement, knowledge, conduct,

document, or omission allegedly attributable to one defendant is attributable to another.

To the extent a response is required, Defendants deny the allegations in Paragraph 45.

      C.     Relevant Non-Parties

46. At all times relevant to this action, ModivCare was a public corporation, organized and
    existing under the laws of the State of Delaware with its principal place of business
    and principal executive offices located at 6900 Layton Avenue, 12th Floor, Denver,
    Colorado 80237. Throughout the Class Period, the Company’s securities were traded
    on the NASDAQ, a national exchange, under the ticker symbol “MODV.” On August
    20, 2025, ModivCare filed for voluntary Chapter 11 bankruptcy protection. On August
    28, 2025, the Company’s common stock was suspended from trading on the NASDAQ
    and delisted. Thereafter, ModivCare’s common stock began trading on the over-the-
    counter markets (“OTCMKTS”) under the ticker MODVQ.


                                            26


Case No. 1:25-cv-00306-GPG-KAS          Document 79     filed 10/05/26   USDC Colorado
                                       pg 27 of 269


         ANSWER: Defendants admit that ModivCare was a corporation organized under

the laws of the State of Delaware with its principal place of business and principal

executive offices located at 6900 E Layton Avenue, 12th Floor, Denver, Colorado 80237;

that ModivCare’s common stock traded on the NASDAQ under the ticker symbol “MODV”

during the alleged Class Period; that ModivCare filed for voluntary protection under

Chapter 11 of the Bankruptcy Code on August 20, 2025; that ModivCare’s common stock

was delisted from trading on the NASDAQ on August 28, 2025; and that ModivCare’s

common stock thereafter traded on OTCMKTS under the ticker symbol “MODVQ.” Except

as expressly admitted, Defendants deny the allegations in Paragraph 46.

47. CW1 was a ModivCare employee from before the Class Period until Q3 2023. As part
    of CW1’s responsibilities, CW1 managed the Company’s multi-million-dollar NEMT
    contracts to provide transportation to payors’ members. CW1 was also responsible for
    de-implementations, which refers to ending payors’ contracts with ModivCare.
         ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning CW1 in Paragraph 47 and deny them on that

basis.

48. In CW1’s role, CW1 had access to all of the information regarding the Company’s
    NEMT contracts, including the payors, the contracts’ dollar amount, the members, the
    number of members for each contract, “and basically everything in the contract, to
    understand what it would take for us to provide the service.”
         ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning CW1 in Paragraph 48 and deny them on that

basis.

49. CW1 was responsible for coordinating with upper management, including senior vice
    presidents and presidents, at insurance and healthcare companies to set those payors
    up on ModivCare’s system, help them understand the technology, and set the payor


                                           27


Case No. 1:25-cv-00306-GPG-KAS          Document 79     filed 10/05/26   USDC Colorado
                                       pg 28 of 269


   up with the transportation providers that ModivCare works with in the states applicable
   to the payors’ contract. According to CW1, ModivCare’s implementation phase for a
   new payor typically lasted between 90 and 120 days but could last up to 9 months,
   depending on the payor.
         ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning CW1 in Paragraph 49 and deny them on that

basis.

50. CW1 also worked on ModivCare’s strategic initiatives with the Company’s operations
    teams across the country to improve operational performance, start new initiatives to
    improve operational efficiencies, and help the Home Health and NEMT divisions.
         ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning CW1 in Paragraph 50 and deny them on that

basis.

51. CW2 served as ModivCare’s VP of Transportation before the Class Period and into
    2024. CW2 was also responsible for overseeing profit and loss performance for all the
    contracts in CW2’s region.
         ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning CW2 in Paragraph 51 and deny them on that

basis.

52. CW2’s daily responsibilities included maintaining customer relationships, meeting
    regularly with health plans, and ensuring that the Company was meeting contractual
    metrics by reducing missed rides, increasing on-time performance, and improving
    service delivery. CW2 also managed the network development team, which was
    tasked with expanding provider networks and improving service delivery. As of
    September 2022, CW2 reported to Senior VP of Transportation, Chris Heine, who
    reported to the President of ModivCare’s Mobility Division, Illias Simpson. In CW2’s
    role, CW2 had “tons” of meetings with the Senior VP of Transportation that were
    largely focused on operations but occasionally involved financial discussions focused
    on customers’ outstanding balances. CW2 also participated in Monthly Leadership


                                           28


Case No. 1:25-cv-00306-GPG-KAS           Document 79      filed 10/05/26   USDC Colorado
                                        pg 29 of 269


      Meetings with the President of ModivCare’s Mobility Division and in general leadership
      meetings with Defendant Sampson.
         ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the allegations concerning CW2 in Paragraph 52 and deny them on that

basis.

53. CW3 was employed by ModivCare as a Director of Proposal Management and
    Marketing Communication prior to the Class Period through April 2023 and as a Senior
    Director of Proposal Management from April 2023 through September 2023. CW3
    oversaw a team of approximately 12 employees who were responsible for identifying
    and pursuing new contract opportunities nationwide, monitoring aggregated bid sites
    for solicitations, preparing and submitting proposals, supporting the sales team with
    pipeline and reporting information, and coordinating with other departments to develop
    implementation plans for awarded contracts. CW3 initially reported to Senior VP of
    Government Affairs Robert Pittman, then to Senior VP of Strategic Solutions Seth
    Ravine.
         ANSWER: Defendants admit and allege that CW3 is LeKesh Pettis. Dkt. 55.

Defendants lack knowledge or information sufficient to form a belief as to the truth of the

remaining allegations in Paragraph 53 and deny them on that basis. Except as expressly

admitted, Defendants deny the allegations in Paragraph 53.

IV.      SUBSTANTIVE ALLEGATIONS

         A.     ModivCare is a Healthcare Services Company Whose Core Business
                is Providing Non-Emergency Medical Transportation

54. ModivCare purports to be a technologically-enabled healthcare services company that
    offers NEMT services, personal care services (“PCS”) and remote patient monitoring
    solutions (“RPM”) throughout the United States. During the Class Period, ModivCare
    had four reportable business segments: NEMT, PCS, RPM, and Corporate and Other.
    The Company and its employees would sometimes refer to its NEMT business
    segment as its Mobility division, and its PCS and RPM businesses as its Home division.
         ANSWER: Defendants admit that, during the alleged Class Period, ModivCare

was a technology-enabled healthcare services company that provided non-emergency


                                              29


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                      pg 30 of 269


medical transportation, personal care services, and remote patient monitoring solutions

in the United States; that ModivCare had four reportable segments: NEMT, Personal Care

Services, Remote Patient Monitoring, and Corporate and Other; and that ModivCare

referred to its NEMT segment as its Mobility division and to its Personal Care Services

and Remote Patient Monitoring segments collectively as its Home division. To the extent

Paragraph 54 characterizes or quotes from ModivCare’s public statements or other SEC

filings, Defendants respectfully refer the Court to the complete documents, which speak

for themselves, and deny any allegations inconsistent therewith. Except as expressly

admitted, Defendants deny the allegations in Paragraph 54.

55. ModivCare’s core business is NEMT, which consists of coordinating and managing
    non-emergency medical transportation services. The Company generates the vast
    majority of its revenue from NEMT services. For instance, in its financial and
    operational report for the fourth quarter and full year ended December 31, 2024, which
    was filed with the SEC on March 6, 2025 on Form 10-K (the “FY2024 Form 10-K”),
    ModivCare reported the following net service revenues:


      ANSWER: Defendants admit that, during the alleged Class Period, NEMT was one

segment of ModivCare’s business and that ModivCare filed its FY2024 Form 10-K with

the SEC on March 6, 2025. Paragraph 55 characterizes or quotes from ModivCare’s

FY2024 Form 10-K, and Defendants respectfully refer the Court to the complete

document, which speaks for itself, and deny any allegations inconsistent therewith.

Except as expressly admitted, Defendants deny the allegations in Paragraph 55.


                                           30


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 31 of 269


56. The Company purports to be the largest manager of NEMT programs for state
    governments and managed care organizations in the United States. During the Class
    Period, ModivCare provided NEMT services in 48 states and the District of Columbia
    to approximately between 33.6 and 36 million members. To facilitate this, ModivCare
    partners with credentialed transportation providers, including third-party transportation
    providers, on-demand transportation companies, mass transit entities, mileage
    reimbursement programs, taxis, and county-based emergency medical service
    providers, to supply transportation tailored to members individualized health needs.
    The members are typically Medicaid or Medicare eligible and have limited mobility or
    financial resources.
       ANSWER: Defendants admit that, during the alleged Class Period, ModivCare

was the United States’s largest manager of NEMT programs for state governments and

managed care organizations; that ModivCare provided NEMT services in 48 states and

the District of Columbia; that ModivCare provided NEMT services through a network of

credentialed third-party transportation providers using a variety of transportation modes;

and that members were typically eligible for Medicaid or Medicare. Paragraph 56

characterizes or quotes from ModivCare’s public statements and SEC filings, and

Defendants respectfully refer the Court to the complete recordings or documents, which

speak for themselves, and deny any allegations inconsistent therewith. Except as

expressly admitted, Defendants deny the allegations in Paragraph 56.

       B.     ModivCare’s NEMT Customers Largely Consists of State Medicaid
              Programs and MCOs

57. For its NEMT business, ModivCare’s customers primarily consist of state Medicaid
    programs and MCOs, the latter of which are health plans (such as Medicare
    Advantage) or healthcare companies that manage the delivery of healthcare services
    to its members while aiming to balance costs with maintaining quality service. The
    Company contracts with these customers (sometimes referred to as “payors”) to
    provide NEMT services to the payors’ members. The Company’s top 6 payors
    included UnitedHealthcare, Aetna, Humana, Anthem, Health Care Service
    Corporation (“HCSC”) and Centene.


                                             31


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                      pg 32 of 269


      ANSWER: Defendants admit that, during the alleged Class Period, ModivCare’s

NEMT customers included state Medicaid programs, managed care organizations, and

healthcare companies; that ModivCare’s customers were referred to as payors; and that

ModivCare contracted with those payors to provide NEMT services to their members.

Except as expressly admitted, Defendants deny the allegations in Paragraph 57.

58. According to the Company’s FY2024 Form 10-K, ModivCare enters contracts with
    state Medicaid contracts that generally cover a three-to-five-year period and contain
    “multiple renewal options.” By contrast, ModivCare’s contracts with MCOs typically
    continue until either party, with reasonable notice, terminates the agreement, and
    purportedly “allow for regular price adjustments based upon utilization and
    transportation cost.” Utilization refers to the rate at which ModivCare’s customers’
    members use the Company’s NEMT services. The Company reports utilization as a
    monthly average and on a quarterly basis.
      ANSWER: Defendants admit that, during the alleged Class Period, certain of

ModivCare’s state Medicaid contracts generally covered a three-to-five-year period and

that certain of ModivCare’s contracts with MCOs continued until either party terminated

the contract. Defendants further admit and allege that utilization referred to the rate at

which members used ModivCare’s NEMT services and that ModivCare disclosed

utilization quarterly. Paragraph 58 characterizes or quotes from ModivCare’s FY2024

Form 10-K, and Defendants respectfully refer the Court to the complete document, which

speaks for itself, and deny any allegations inconsistent therewith. Except as expressly

admitted, Defendants deny the allegations in Paragraph 58.

59. ModivCare overwhelmingly derived its NEMT revenue from Medicaid contracts.
    Indeed, according to the Company’s February 22, 2024 investor presentation (the
    “4Q2023 Investor Presentation”) and March 6, 2025 investor presentation (the
    “4Q2024 Investor Presentation”), approximately 83%, 82% and 85% of NEMT
    revenue in 2022, 2023 and 2024, respectively, was attributable to Medicaid contracts.


                                           32


Case No. 1:25-cv-00306-GPG-KAS        Document 79      filed 10/05/26   USDC Colorado
                                     pg 33 of 269


   The remaining revenue was generated from Medicare contracts. This revenue
   breakdown remained consistent throughout the Class Period.
      ANSWER: Defendants admit that, during the alleged Class Period, ModivCare

received revenue from its Medicaid contracts. Paragraph 59 characterizes or quotes from

ModivCare’s February 22, 2024 and March 6, 2025 investor presentations, and

Defendants respectfully refer the Court to the complete documents, which speak for

themselves, and deny any allegations inconsistent therewith. Except as expressly

admitted, Defendants deny the allegations in Paragraph 59.

60. ModivCare also earns a significant portion of its NEMT revenue from a small number
    of key customers. For instance, according to ModivCare’s FY2024 Form 10-K, a single
    state Medicaid agency accounted for around 10.9%, 11.2%, and 10.9% of the
    Company’s NEMT revenue in 2022, 2023, and 2024, respectively. ModivCare earned
    approximately 19.8%, 19.8%, and 22.4% of its NEMT revenue in 2022, 2023, and
    2024 from its next four largest NEMT customers combined.
      ANSWER: Paragraph 60 characterizes or quotes from ModivCare’s FY2024 Form

10-K, and Defendants respectfully refer the Court to the complete document, which

speaks for itself, and deny any allegations inconsistent therewith. Except as expressly

admitted, Defendants deny the allegations in Paragraph 60.

      C.     ModivCare Primarily Utilizes Three Contract Structures for its NEMT
             Customers

61. ModivCare primarily utilizes three contract structures for its NEMT customers: (i)
    capitated full-risk; (ii) capitated shared risk; and (iii) fee-for-service.
      ANSWER: Defendants admit that, during the alleged Class Period, ModivCare

used capitated full-risk contracts, capitated shared-risk contracts, and fee-for-service

contracts with its NEMT customers. Except as expressly admitted, Defendants deny the

allegations in Paragraph 61.


                                          33


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                       pg 34 of 269


62. Under both capitated contracts and fee-for-service structures, ModivCare arranges for
    transportation of members through its network of independent transportation providers,
    whereby ModivCare negotiates rates and remits payment to the transportation
    providers. According to the Company’s FY2024 Form 10-K, to determine the per ride
    or per mile rates paid under its transportation service contracts, ModivCare purports
    to use pricing models for specific populations that “take into account factors such as
    estimated utilization, state specific data, previous experience in the state or with
    similar services, the medically covered programs outlined in the contract, identified
    populations to be serviced, estimated volume, estimated transportation provider rates
    and availability of mass transit.”
       ANSWER: Defendants admit that, during the alleged Class Period, under either

capitated or fee-for-service contracts, ModivCare arranged transportation through a

network of independent transportation providers with which it negotiated rates and to

which it remitted payment. Defendants further admit and allege that, during the alleged

Class Period, ModivCare used pricing models that considered specific factors for specific

populations to determine applicable contract rates. Paragraph 62 characterizes or quotes

from ModivCare’s FY2024 Form 10-K, and Defendants refer the Court to the complete

document, which speaks for itself, and deny any allegations inconsistent therewith.

Except as expressly admitted, Defendants deny the allegations in Paragraph 62.

              1.     Full-Risk and Shared Risk Capitated Contracts

63. Capitation refers to “a health care payment method in which medical providers or
    health plan administrators are paid a pre-determined dollar amount for each patient
    assigned to them, regardless of how much medical care they provide to that patient.”1
    Under this payment method, providers are incentivized to provide all of the necessary
    care to a patient for a total cost under the capitated rate for said patient so that the
    provider can retain difference in cost as profit.


1
        [Footnote     1      in      Complaint]         “What       is      capitation?”,
https://www.healthinsurance.org/glossary/capitation/ (last accessed Jan. 9, 2026).

                                            34


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                      pg 35 of 269


      ANSWER: Paragraph 63 and footnote 1 state legal conclusions to which no

response from Defendants is required. To the extent a response is required, Defendants

admit that, during the alleged Class Period, under ModivCare’s capitated contracts,

payors paid a fixed amount per eligible member. Defendants lack knowledge or

information sufficient to form a belief as to the truth of the allegations regarding the

incentives of unidentified providers, and deny them on that basis. Except as expressly

admitted, Defendants deny the allegations in Paragraph 63 and footnote 1.

64. For both its full-risk and shared risk capitated contracts, ModivCare receives a fixed
    PMPM for eligible members in a specific geography. ModivCare negotiates the fixed
    PMPM fee with its customers during the bidding process, and purports to base this
    figure on “actual historical transportation data for the subject geographic region as
    provided by the payor, actuarial work performed in-house as well as by third party
    actuarial firms and actuarial analysis provided by the payor.”
      ANSWER: Defendants admit that, during the alleged Class Period, for both its

capitated full-risk and capitated shared risk contracts, ModivCare received a fixed per-

member per-month fee for eligible members in a specified geography. Defendants further

admit that, during the alleged Class Period, ModivCare determined the per-member per-

month fee with payors during the bidding process, and the fee was based on actual

historical transportation data for the subject geographic region as provided by the payor,

actuarial work performed in-house as well as by third party actuarial firms, and actuarial

analysis provided by the payor. Paragraph 64 characterizes or quotes from ModivCare’s

FY2024 Form 10-K, and Defendants respectfully refer the Court to the complete

document, which speaks for itself, and deny any allegations inconsistent therewith.

Except as expressly admitted, Defendants deny the allegations in Paragraph 64.


                                           35


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26   USDC Colorado
                                       pg 36 of 269


65. For its capitated full-risk contracts, ModivCare receives a pre-negotiated, fixed fee
    from a payor for each of the payor’s eligible members per month and is responsible
    for providing NEMT services to each of those members, regardless of the actual cost
    of care. This means that, under capitated full-risk contracts, ModivCare receives the
    same PMPM fee for a member who does not use any NEMT services during the month
    as it does for a member who frequently uses NEMT services during the month. As
    such, ModivCare’s revenue under its full-risk contracts fluctuates based on costs and
    utilization. (i.e., the rate at which members use ModivCare’s NEMT services, or paid
    trips per member).
      ANSWER: Defendants admit that, during the alleged Class Period, under its

capitated full-risk contracts, ModivCare received a pre-negotiated, fixed per-member per-

month fee for each eligible member and assumed responsibility for the cost of service.

Except as expressly admitted, Defendants deny the allegations in Paragraph 65.

66. With capitated shared risk contracts, the Company also receives an upfront fixed fee
    from a payor for each of the payor’s eligible members per month, but after the monthly
    ridership per member is determined, the PMPM fee adjusted through a true-up
    process to account for the actual realized transportation volumes or costs that may
    result in refunds to the payor (contract payables), or additional payments due from the
    payor (contract receivables) based on the contractually agreed upon provisions. As
    such, the PMPM fee obtained by ModivCare increases or decreases based on
    transportation costs and utilization. CW3 explained that ModivCare’s capitated shared
    risk contracts varied by customer and used historical utilization data as the basis to
    structure each agreed upfront payment by mapping out a risk-sharing plan tied to
    those past trends.
      ANSWER: Defendants admit that, during the alleged Class Period, under

ModivCare’s capitated shared risk contracts, the per-member per-month fee was subject

to a process that adjusted the fee based on actual realized transportation volumes or

costs and may have resulted in a contract payable or a contract receivable. Defendants

lack knowledge or information sufficient to form a belief as to the truth of the CW


                                            36


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 37 of 269


allegations in Paragraph 66 and deny them on that basis. Except as expressly admitted,

Defendants deny the allegations in Paragraph 66.

67. ModivCare offered three different reconciliations provisions for its capitated shared
    risk contracts: (i) reconciliation; (ii) risk corridor; and (iii) profit rebate.
       ANSWER: Defendants admit that, during the alleged Class Period, ModivCare’s

capitated shared risk contracts may have contained reconciliation, risk corridor, or profit

rebate provisions. Except as expressly admitted, Defendants deny the allegations in

Paragraph 67.

68. For capitated contracts with reconciliation provisions, ModivCare receives a partial
    payment as prepayment during the month that the service is provided. The
    prepayments are periodically reconciled against actual trip volume and costs. Thus,
    under a reconciliation provision, ModivCare could either issue a refund to customers
    or receive additional payments depending on a comparison of the PMPM fee with the
    actual cost and/or utilization.
       ANSWER: Defendants admit that, during the alleged Class Period, under its

capitated contracts with reconciliation provisions, ModivCare received monthly capitation

payments as prepayments that were periodically reconciled against actual trip volume

and costs, which may have resulted in a refund to the customer or an additional payment

to ModivCare. Except as expressly admitted, Defendants deny the allegations in

Paragraph 68.

69. With capitated contracts that contain a risk corridor provision, ModivCare and a payor
    negotiate and agree to allow profit within a certain corridor and once those thresholds
    are met, the Company stops recognizing revenue.2 Therefore, through this provision,

2
  [Footnote 2 in Complaint] “‘Risk corridors’ set limits on the dollar amount of risk or gain
that may be experienced for individual patients, e.g., 10% to 20% above or below
capitation payments.” Goodson et al., The Future of Capitation, J Gen Intern Med. 2001
Apr;16(4):250–256, https://pmc.ncbi.nlm.nih.gov/articles/PMC1495203/#ref-list1 (last
accessed Jan. 9, 2026).

                                             37


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26   USDC Colorado
                                       pg 38 of 269


   ModivCare may record an asset (i.e., contract receivable) or liability (i.e., contract
   payable). For instance, if the Company fails to meet the minimum profit established in
   the corridor, it records a contract receivable and should receive additional payment
   from the customer to reach that minimum threshold. On the other hand, if the
   Company reaches the threshold or maximum, then ModivCare will not recognize any
   additional revenue but instead, records a contract payable and will either reduce that
   amount via future increases in trip volume or periodic settlements with the customer.
      ANSWER: Defendants admit that, during the alleged Class Period, under its

capitated contracts with risk corridor provisions, ModivCare and the customer agreed to

allow profit within a certain corridor, and that ModivCare ceased recognizing revenue

once the threshold had been met. Defendants further admit that, during the alleged Class

Period, such contracts may have resulted in ModivCare recording a contract receivable

or a contract payable. Except as expressly admitted, Defendants deny the allegations in

Paragraph 69 and footnote 2.

70. For capitated contracts with profit rebate provision, ModivCare and a payor negotiate
    and agree to a maximum profit and once that threshold is met, the Company stops
    recognizing revenue. Thus, a profit rebate provision can only result in ModivCare
    recording a contract payable.
      ANSWER: Defendants admit that, during the alleged Class Period, under its

capitated contracts with profit rebate provisions, ModivCare and the payor may have

agreed to a maximum profit threshold, and ModivCare ceased recognizing revenue once

that threshold had been reached. Except as expressly admitted, Defendants deny the

allegations in Paragraph 70.

71. Accordingly, depending on the contract’s true-up provisions, ModivCare’s capitated
    shared risk contracts purportedly allowed the Company and its payor to share the risk
    of increases in costs and utilization, and featured the lowest gross margin variance of
    the Company’s contracts. Indeed, the Company claimed that the shared risk contracts


                                            38


Case No. 1:25-cv-00306-GPG-KAS         Document 79     filed 10/05/26   USDC Colorado
                                      pg 39 of 269


   would result in margin stabilization since the PMPM fee received would be adjusted
   for the costs to provide the transportation services (see Figure 1 infra).


      ANSWER: Defendants admit that, during the alleged Class Period, the structure

of ModivCare’s shared-risk capitated contracts allowed for margin stabilization as

generally the amount received per-member, per-month was adjusted for the costs to

provide the transportation services. Paragraph 71 and Figure 1 characterize or quote from

ModivCare’s public statements and SEC filings, including its February 22, 2024 investor

presentation, and Defendants respectfully refer the Court to the complete recordings or

documents, which speak for themselves, and deny any allegations inconsistent therewith.

Except as expressly admitted, Defendants deny the allegations in Paragraph 71.

             2.     Fee-for-Service Contracts

72. ModivCare also utilizes fee-for-service (“FFS”) contracts in its NEMT business,
    wherein the Company charges specific fees for each NEMT service that it provides to


                                           39


Case No. 1:25-cv-00306-GPG-KAS           Document 79    filed 10/05/26   USDC Colorado
                                        pg 40 of 269


   a payor’s members. Under this contract structure, the Company agrees to provide
   services based on costs incurred plus a negotiated margin. Similar to capitated full-
   risk contracts, the Company is entirely responsible for the costs associated with
   providing the services and must estimate its costs when determining fees. The fees
   are based on billing rates for specific services or defined membership populations.
      ANSWER: Defendants admit that, during the alleged Class Period, ModivCare

utilized fee-for-service contracts where ModivCare payors paid a pre-arranged specified

amount for each service that ModivCare provided, and these specified amounts were

based on billing rates for specific services or defined membership populations. Except as

expressly admitted, Defendants deny the allegations in Paragraph 72.

73. ModivCare bills and collects a specified amount for each service provided. The FFS
    revenue is recognized during the period in which the services are rendered and is
    reduced by the estimated impact of contractual allowances and policy discounts for
    certain third-party payors.
      ANSWER: Defendants admit that, during the alleged Class Period, under its fee-

for-service contracts, ModivCare billed and collected a specified amount for each service

provided, and that revenue under the fee-for-service contracts was recognized in the

period in which the services were rendered. Except as expressly admitted, Defendants

deny the allegations in Paragraph 73.

      D.     After ModivCare Secures a NEMT Contract, the                    Company’s
             Implementations Team Handles Customer Onboarding

74. ModivCare’s Implementations Team managed customer onboarding after the
    Company obtained a new NEMT customer contract. CW1 provided an example of the
    implementation process using Cigna Healthcare, explaining that if Cigna needed to
    have transportation set up in Sacramento, California for 2,000 members by November
    1st, then the Implementation team would “do everything it takes” to have
    transportation arranged for those members, including setting up metrics that the payor
    and ModivCare would track in connection with ModivCare providing the payors’
    members transportation services, including member satisfaction, responsiveness to


                                            40


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26   USDC Colorado
                                       pg 41 of 269


   complaints, how quickly transportation providers pick up the phone, length of time
   members remained on the phone with transportation providers, response times, and
   other KPIs. According to CW1, ModivCare’s implementation phase for a new payor
   typically lasted between 90 and 120 days but could last up to 9 months, depending on
   the payor.
       ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the CW allegations in Paragraph 74 and deny them on that basis.

Defendants otherwise deny the allegations in Paragraph 74.

75. According to CW1, the Implementation team tracked utilization during the first 30 days
    after a payor’s implementation was complete after which the responsibility for tracking
    utilization transitioned to the Operations team. CW1 explained that utilization was
    definitely a metric that ModivCare tracked carefully.
       ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the CW allegations in Paragraph 75 and deny them on that basis.

Defendants otherwise deny the allegations in Paragraph 75.

       E.    During the COVID-19 Pandemic, ModivCare Experienced a Boon from
             Full Risk Contracts with Low Utilization Which Spurred a Series of
             Costly Acquisitions

76. Prior to the Class Period, in 2020, ModivCare’s contracts were predominantly
    capitated full-risk with approximately 60% of its NEMT revenue derived from such
    contracts. During this time, ModivCare experienced low utilization rates due to the
    COVID-19 pandemic because its customers’ members were making less trips as a
    result of the mandated stay at home orders and rise in telehealth visits.
       ANSWER: Paragraph 76 characterizes ModivCare’s contracts and public

disclosures regarding its NEMT revenue, and Defendants respectfully refer the Court to

the complete documents, which speak for themselves, and deny any allegations

inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 76.

77. For instance, CW2 explained that ModivCare’s full-risk contracts were extremely
    lucrative during the COVID-19 pandemic because the Company collected millions of


                                            41


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26    USDC Colorado
                                       pg 42 of 269


    dollars in PMPM payments but had virtually no transportation costs due to decreased
    utilization as members remained at home. As a result, according to CW2, ModivCare
    experienced a financial boon during the first approximately two years of the COVID-
    19 pandemic.
       ANSWER: Defendants lack knowledge or information sufficient to form a belief as

to the truth of the CW allegations in Paragraph 77 and deny them on that basis.

Defendants otherwise deny the allegations in Paragraph 77.

78. Indeed, according to the Company’s financial report for the fourth quarter and full year
    ended December 31, 2020, which was filed with the SEC on March 1, 2021 on Form
    10-K (the “FY2020 Form 10-K”), ModivCare reported that its 2020 NEMT operating
    income totaled approximately $120,689,000, which was an approximately 488%
    increase from the $24,732,000 reported for its 2019 NEMT operating income. The
    Company primarily attributed the massive increase in NEMT operating income to
    significantly lower service expenses, which were approximately $1,036,288,000 in
    2020 as compared to approximately $1,401,152,000 in 2019.
       ANSWER: Defendants admit that ModivCare filed its FY2020 Form 10-K with the

SEC on March 1, 2021. Paragraph 78 characterizes or quotes from ModivCare’s FY2020

Form 10-K, and Defendants respectfully refer the Court to the complete document, which

speaks for itself, and deny any allegations inconsistent therewith. Except as expressly

admitted, Defendants deny the allegations in Paragraph 78.

79. ModivCare’s NEMT operating income remained elevated during 2021 as compared to
    2019 pre-COVID levels. For instance, according to the Company’s financial report for
    the fourth quarter and full year ended December 31, 2021, which was filed with the
    SEC on March 1, 2021 on Form 10-K (the “FY2021 Form 10-K”), ModivCare reported
    that its 2021 NEMT operating income totaled approximately $73,121,000, which was
    an approximately 196% increase from the $24,732,000 reported for its 2019 NEMT
    operating income:3


3
  [Footnote 3 in Complaint] ModivCare’s increased net service revenues also included
$110.0 million of revenue related to contracts from the National MedTrans, LLC
acquisition that took place in the second quarter of 2020.

                                            42


Case No. 1:25-cv-00306-GPG-KAS            Document 79   filed 10/05/26   USDC Colorado
                                         pg 43 of 269


       ANSWER: Defendants admit that ModivCare filed its FY2021 Form 10-K with the

SEC on March 1, 2022. Paragraph 79, footnote 3, and Plaintiff’s chart characterize or

quote from ModivCare’s FY2021 Form 10-K, and Defendants respectfully refer the Court

to the complete document, which speaks for itself, and deny any allegations inconsistent

therewith. Except as expressly admitted, Defendants deny the allegations in Paragraph

79, footnote 3, and Plaintiff’s chart.

80. Indeed, ModivCare’s executives would later acknowledge that the COVID-19
    pandemic provided a financial windfall to the Company. For example, at the 2023
    Deutsche Bank Conference on October 3, 2023, Defendant Sampson stated:
              [D]uring COVID, obviously, there wasn’t a lot of trips … So we
              benefited heavily from increased cash coming into our
              balance sheet as well as on the P&L as well, but the big
              bolus was on our balance sheet.

       ANSWER: Paragraph 80 characterizes or quotes from ModivCare’s October 3,

2023 Deutsche Bank conference transcript, and Defendants respectfully refer the Court

to the complete recording from that conference, which speaks for itself, and deny any

allegations inconsistent therewith. Defendants otherwise deny the allegations in

Paragraph 80.


                                             43


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                      pg 44 of 269


81. ModivCare utilized its cash surplus along with a series of private senior note
    placements to make a number of acquisitions between 2020 through 2022 that totaled
    over a billion dollars. For instance, according to ModivCare’s FY2024 Form 10-K: (i)
    in 2020, the Company acquired National MedTrans, LLC for $80 million and OEP AM,
    Inc. (“Simplura”) for $575 million; (ii) in 2021, ModivCare spent over $650 million on
    acquisitions, purchasing WellRyde, Care Finders Total Care, and VRI Intermediate
    Holdings; and (iii) in 2022, the Company purchased personal care customer contracts
    from another entity for $7.6 million and also acquired Guardian Medical Monitoring for
    $71.6 million. These acquisitions were intended to grow ModivCare’s Mobility and
    Home divisions while creating opportunities for cross-selling services and meeting
    payor’s desires for a one-stop shop.
      ANSWER: Defendants admit that ModivCare acquired National MedTrans, LLC

and OEP AM, Inc. in 2020; WellRyde, Care Finders Total Care, and VRI Intermediate

Holdings in 2021; and personal care customer contracts and Guardian Medical Monitoring

in 2022, in each case for the amount reported in ModivCare’s SEC filings. Paragraph 81

characterizes or quotes from ModivCare’s FY2024 Form 10-K. Defendants respectfully

refer the Court to the complete document, which speaks for itself, and deny any

allegations inconsistent therewith. Except as expressly admitted, Defendants deny the

allegations in Paragraph 81.

      F.     Leading Up to the Class Period, ModivCare Shifts from Capitated Full-
             Risk Contracts to Primarily Capitated Shared Risk Contracts

82. After the COVID-19 lockdowns, the Company began to renegotiate its NEMT
    contracts to shift away from capitated full-risk to capitated shared risk.
      ANSWER: Defendants admit that ModivCare and certain payors renegotiated

certain NEMT contracts from full-risk capitated contracts to shared-risk capitated

contracts. Except as expressly admitted, Defendants deny the allegations in Paragraph

82.


                                           44


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 45 of 269


83. Prior to that shift, the Company’s revenue from full-risk and shared risk capitated
    contracts was approximately 60% and 25%, respectively. By 2Q 2021, ModivCare
    reported that, of the approximately 85% of NEMT revenue that was capitated (with the
    remaining 15% of NEMT revenue being FFS), approximately 44% and 41% were
    attributable to full-risk and shared risk, respectively. ModivCare’s capitated NEMT
    revenue remained divided roughly in half between full-risk and shared risk capitated
    contracts, respectively, until the beginning of the Class Period. By 1Q 2023,
    ModivCare reported that, of the approximately 85% of NEMT revenue that was
    capitated, approximately 20% and 65% were attributable to full-risk and shared risk,
    respectively.
       ANSWER: Paragraph 83 characterizes or quotes from ModivCare’s public

statements and SEC filings regarding its NEMT revenue, and Defendants respectfully

refer the Court to the complete recordings or documents, which speak for themselves,

and deny any allegations inconsistent therewith. Defendants otherwise deny the

allegations in Paragraph 83.

84. This transition from capitated full-risk to shared risk contracts had significant
    implications for ModivCare’s balance sheet because, as described in §IV.C.1 supra,
    those contracts contained reconciliation, risk corridor, or profit rebate provisions that
    could result in the Company booking a contract receivable or contract payable
    depending on service costs and member utilization. For instance, prior to the Class
    Period during the Company’s June 23, 2022 inaugural Investor Day (the “2022
    Investor Day”), Sampson explained that ModivCare “expect[ed]” contracts payable
    and contracts receivable to “go up, go down” because it would reflect that “the
    contracts are operating as designed” and added that the Company would “explain that
    on a quarterly basis how it’s fluctuating[.]”
       ANSWER: Paragraph 84 states a legal conclusion to which no response is

required. To the extent a response is required, Paragraph 84 characterizes or quotes from

ModivCare’s June 23, 2022 Investor Day presentation, and Defendants respectfully refer

the Court to the complete document, which speaks for itself, and deny any allegations

inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 84.


                                             45


Case No. 1:25-cv-00306-GPG-KAS           Document 79      filed 10/05/26    USDC Colorado
                                        pg 46 of 269


85. Despite the fluctuation, Defendants claimed that the shift to capitated shared risk
    contracts would protect ModivCare’s margins and provide more stability, including by
    normalizing working capital and thereby cash flow. 4 Given that the shared risk
    contracts’ structure purportedly allowed ModivCare to pass through increased costs
    to its customers (thereby protecting ModivCare’s downside risk) while limiting the
    Company’s ability to profit from unused services (thereby protecting payors’ downside
    risks), Defendants’ characterized its shared risk contracts as “win-win” throughout the
    Class Period.
       ANSWER: Defendants admit that, during the alleged Class Period, shared-risk

capitated contracts were structured to allow for margin stabilization because generally the

amount of the per-member, per-month fee would be adjusted for the costs to provide the

transportation services. Paragraph 85 characterizes or quotes from ModivCare’s public

statements and SEC filings. Defendants respectfully refer the Court to the complete

recordings and documents, which speak for themselves, and deny any allegations

inconsistent therewith. Except as expressly admitted, Defendants deny the allegations in

Paragraph 85 and footnote 4.

86. Indeed, during the Company’s earnings call for the third quarter of 2022 on November
    3, 2022 (the “3Q2022 Earnings Call”), Defendant Sampson explained that
    ModivCare’s shared risk contracts allowed the Company to “pass a large chunk” of
    “higher cost[s] in [] mobility” onto customers, “protecting the downside in the event that
    there’s some volatility in costs or utilization.” Likewise, during the May 10, 2023 Bank
    of America Securities Health Care Conference and earnings call for the third quarter
    of 2023 on November 3, 2023 (the “3Q2023 Earnings Call”), Sampson explained that
    the shared risk contracts’ win-win nature provided ModivCare with “stable rigid


4
   [Footnote 4 in Complaint] Working capital is the amount of money a company has
available to operate after deducting its current liabilities (i.e., accounts payable and debt)
from its current assets (i.e., cash, accounts receivable, etc.). See Jason Fernando,
Working Capital: Formula Components, and Limitations, Investopedia (June 17, 2025),
https://www.investopedia.com/terms/w/workingcapital.asp (last accessed Jan. 9, 2026).


                                             46


Case No. 1:25-cv-00306-GPG-KAS           Document 79      filed 10/05/26   USDC Colorado
                                        pg 47 of 269


   margins regardless of utilization and cost” and “protect[ed] the downside to [the
   Company’s] cash flow,” respectively.
       ANSWER: Defendants need not respond to the allegations in Paragraph 86 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. Paragraph 86 characterizes or quotes from ModivCare’s

November 3, 2022, May 10, 2023, and November 3, 2023 earnings call and conference

transcripts, and Defendants respectfully refer the Court to the complete recordings of

those earnings calls, which speak for themselves, and deny any allegations inconsistent

therewith. Defendants otherwise deny the allegations in Paragraph 86.

87. Defendants also provided insight into the mechanics of the shared risk true- up
    process. For instance, in a slide from ModivCare’s August 2023 investor presentation
    (“2Q2023 Investor Presentation”), the Company represented that shared risk
    contracts maintained the same net cash flow regardless of utilization due to the
    contracts “built-in corridors[,]” which allowed ModivCare to make profit up to a certain
    threshold. After that threshold is met, ModivCare stops recognizing revenue and
    records a liability within the accrued contract payable account.
       ANSWER: Paragraph 87 characterizes or quotes from ModivCare’s Q2 FY2023

investor presentation. Defendants respectfully refer the Court to the complete document,

which speaks for itself, and deny any allegations inconsistent therewith. Defendants

further deny that any alleged statement, knowledge, conduct, document, or omission

allegedly attributable to one defendant is attributable to another. Defendants otherwise

deny the allegations in Paragraph 87.

88. To demonstrate how the corridors function, the Company modeled three utilization
    scenarios in the slide. In the low utilization scenario, transportation costs decrease by


                                             47


Case No. 1:25-cv-00306-GPG-KAS          Document 79      filed 10/05/26   USDC Colorado
                                       pg 48 of 269


   $4 per member with ModivCare recording $2 in a contract payable that it will eventually
   repay the customer due to lower costs than anticipated. In the high utilization scenario,
   transportation costs increase by $4 per member with ModivCare recording $2 in a
   contract receivable that it will eventually receive from the customer to share the higher
   than anticipated costs. Based on this, ModivCare represented that the “[s]hared risk
   structure reduce[d] income statement impact from changes in costs with the built-in
   corridors” (see Figure 2 infra).


      ANSWER: Paragraph 88 characterizes or quotes from ModivCare’s Q2 FY2023

investor presentation, and Defendants respectfully refer the Court to the complete

document, which speaks for itself, and deny any allegations inconsistent therewith.

Defendants otherwise deny the allegations in Paragraph 88.

      G.     During the Class Period, ModivCare’s Free Cash Flow Plummets and
             Debt Balloons Due to COVID-19 Rebates, Loss of Customers due to
             Service Issues, Increased Utilization, and Collectability Issues

             1.     ModivCare Reimburses Customers Hundreds of Millions of
                    Dollars for Low Utilization During COVID-19


                                            48


Case No. 1:25-cv-00306-GPG-KAS           Document 79     filed 10/05/26   USDC Colorado
                                        pg 49 of 269


89. Though ModivCare’s NEMT operating income and cash position benefited
    significantly from low utilization during the COVID-19 pandemic, those financial
    windfalls were offset by swelling contract payables balances leading up to the Class
    Period.
      ANSWER: Defendants admit that utilization of NEMT services declined during the

COVID-19 pandemic, and that ModivCare’s contract payables balances increased prior

to the start of the alleged Class Period. Except as expressly admitted, Defendants deny

the allegations in Paragraph 89.

90. For instance, according to the FY2020 Form 10-K, ModivCare’s total accrued and
    long-term contract payable balances for 2020 was $173,778,000. These balances
    represented overpayments and liability reserves related to lower activity due to
    COVID-19 and corresponded to ModivCare’s reconciliation and risk corridor contracts
    (i.e., ModivCare’s shared risk contracts). In other words, although ModivCare’s shared
    risk contracts represented only a portion of ModivCare’s contract mix in 2020, the
    Company was responsible for repaying a significant sum as a result of lower utilization
    during COVID-19.
      ANSWER: Paragraph 90 characterizes or quotes from ModivCare’s FY2020 Form

10-K, and Defendants respectfully refer the Court to the complete document, which

speaks for itself, and deny any allegations inconsistent therewith. Defendants otherwise

deny the allegations in Paragraph 90.

91. By 1Q 2021, ModivCare’s total accrued contract payable balance related to shared
    risk contracts had surged to $245,386,000. Given the true-up aspect of its shared risk
    contracts, ModivCare anticipated continuing to reimburse those customers for COVID-
    19 under-utilization. By contrast, ModivCare did not expect to repay most of its full-
    risk customers for COVID-19 related under-utilization. However, according to CW2,
    some of ModivCare’s health plan customers requested refunds due to the inactivity
    and in some cases, the Company partially refunded payments “in the spirit of good
    partnership.”
      ANSWER: Paragraph 91 characterizes or quotes from ModivCare’s public

statements or SEC filings, and Defendants respectfully refer the Court to the complete


                                            49


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 50 of 269


documents, which speak for themselves, and deny any allegations inconsistent therewith.

Defendants lack knowledge or information sufficient to form a belief as to the truth of the

CW allegations in Paragraph 91 and deny them on that basis. Defendants otherwise deny

the allegations in Paragraph 91.

92. Indeed, during the Company’s earnings call for the first quarter of 2021 on May 7,
    2021 (“1Q2021 Earnings Call”), Defendant Sampson confirmed that ModivCare had
    reimbursed some of its full risk customers, stating:
              As a reminder, our full risk contracts are structured, so we
              bear all the expense management and market fluctuation risk.
              Our customers with full risk contract models are fully aware of
              the performance during the pandemic.

              For some, we have provided or expect to provide
              retroactive monetary rebates or prospective rate
              concessions. However, for the majority, we do not expect to
              provide any concessions.

       ANSWER: Paragraph 92 characterizes or quotes from ModivCare’s May 7, 2021

earnings call, and Defendants respectfully refer the Court to the complete recording from

that earnings call, which speaks for itself, and deny any allegations inconsistent therewith.

Defendants otherwise deny the allegations in Paragraph 92.

93. As such, throughout 2021 and leading up to the beginning of the Class Period on
    November 3, 2022, ModivCare’s total contracts payable exceeded its net accounts
    receivable, as depicted in Figure 3:


                                             50


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26    USDC Colorado
                                       pg 51 of 269


       ANSWER: Paragraph 93 and Figure 3 characterize or quote from ModivCare’s

public statements and SEC filings describing its contracts payables and contracts

receivables balances, and Defendants respectfully refer the Court to the complete

recordings and documents, which speak for themselves, and deny any allegations

inconsistent therewith. Defendants otherwise deny the allegations in Paragraph 93 and

Figure 3.

94. At the start of the Class Period, ModivCare began to pay down its massive contract
    payables balance. For instance, during the 3Q2022 Earnings Call on November 3,
    2022, Defendant Sampson stated that ModivCare “reduced [its] contract payable
    balance, net of our contract receivables, by $51 million to a net balance of $184 million”
    and added that the Company “expect[ed] to reduce this net balance by an additional
    $40 million to $60 million during the fourth quarter” of 2022.
       ANSWER: Paragraph 94 characterizes or quotes from ModivCare’s November 3,

2022 earnings call, and Defendants respectfully refer the Court to the complete recording


                                             51


Case No. 1:25-cv-00306-GPG-KAS         Document 79      filed 10/05/26   USDC Colorado
                                      pg 52 of 269


from that call, which speaks for itself, and deny any allegations inconsistent therewith.

Defendants otherwise deny the allegations in Paragraph 94.

95. By the end of the fourth quarter of 2022 (“4Q2022”), according to its financial and
    operational report for the fourth quarter and full year ended December 31, 2022, which
    was filed with the SEC on March 7, 2023 on Form 10-K (the “FY2022 Form 10-K”),
    the Company reduced its contract payables to $194.3 million.
      ANSWER: Defendants admit that ModivCare filed its FY2022 Form 10-K with the

SEC on March 7, 2023. Paragraph 95 characterizes or quotes from ModivCare’s FY2022

Form 10-K, and Defendants respectfully refer the Court to the complete document, which

speaks for itself, and deny any allegations inconsistent therewith. Except as expressly

admitted, Defendants deny the allegations in Paragraph 95.

96. These payments decimated ModivCare’s cash position. Indeed, after paying $134
    million to reduce its contracts payables balance in 2022, the Company ended the
    fourth quarter of 2022 with $14.5 million in cash. Nevertheless, Defendants assured
    investors that the Company’s cash position would normalize.
      ANSWER: Paragraph 96 characterizes or quotes from ModivCare’s FY2022 Form

10-K. Defendants respectfully refer the Court to the complete document, which speaks

for itself, and deny any allegations inconsistent therewith. Defendants further deny that

any alleged statement, knowledge, conduct, document, or omission allegedly attributable

to one defendant is attributable to another. Defendants otherwise deny the allegations in

Paragraph 96.

97. For instance, during the Company’s February 23, 2023 fourth quarter and full-year
    2022 earnings call (“FY2022 Earnings Call”), Defendant Shepard stated: “As a
    reminder, we expect a more normalized level of activity for these contracts payable
    moving forward and, therefore, a more normalized environment for our free cash flow
    in 2023.”


                                           52


Case No. 1:25-cv-00306-GPG-KAS         Document 79     filed 10/05/26   USDC Colorado
                                      pg 53 of 269


      ANSWER: Paragraph 97 characterizes or quotes from ModivCare’s February 23,

2023 earnings call, and Defendants respectfully refer the Court to the complete recording

from that earnings call, which speaks for itself, and deny any allegations inconsistent

therewith. Defendants otherwise deny the allegations in Paragraph 97.

98. Likewise, during the same earnings call, Defendant Sampson represented the
    3Q2022 and 4Q2022 payments were the final ones to pay off the balances incurred
    under the Company’s shared risk contracts during the COVID-19 pandemic, stating in
    relevant part: “2022 involves us paying off the cash that we accumulated on our
    balance sheet through COVID in 2020 and 2021 and the bulk of accumulation -- or a
    disproportional amount of that accumulation was all paid off in 2022. So the COVID
    payoff was finished in 2022.” With COVID-19 payments purportedly complete,
    Defendants assured that ModivCare’s working capital fluctuations would normalize
    under the shared risk contracts and as a result, the Company would generate more
    free cash flow each quarter going forward.
      ANSWER: Paragraph 98 characterizes or quotes from ModivCare’s February 23,

2023 earnings call, and Defendants respectfully refer the Court to the complete recording

from that earnings call, which speaks for itself, and deny any allegations inconsistent

therewith. Defendants further deny that any alleged statement, knowledge, conduct,

document, or omission allegedly attributable to one defendant is attributable to another.

Defendants otherwise deny the allegations in Paragraph 98.

             2.     ModivCare’s NEMT Service Quality Issues and Outdated
                    Technologies Cause a Swell of Member Complaints, Significant
                    Customer Issues, and Contract Losses

99. Prior to and throughout the Class Period, ModivCare received increasing complaints
    about its NEMT service and technological platforms, which caused payors to be
    dissatisfied and led them to place the Company on performance improvement plans
    and to delay payments, seek liquidated damages, and cancel contracts.
      ANSWER: Defendants need not respond to the allegations in Paragraph 99 to the

extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and


                                           53


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 54 of 269


10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the allegations concerning

unidentified payors’ states of mind in Paragraph 99 and deny them on that basis.

Defendants otherwise deny the allegations in Paragraph 99.

100. For instance, around 1Q2022, CW1 began hearing that account managers had
   “struggles to keep the payors happy.” According to CW1, beginning around May or
   June 2022 and continuing throughout CW1’s tenure, ModivCare received increasing
   complaints from payors’ members, including reports that drivers were not showing up
   on time and of miscommunications between drivers and payors. CW1 recalled that
   account managers’ challenges and the increase in member complaints coincided with
   Simpson’s appointment as President of the Mobility Division in April 2022, and
   explained that with his appointment ModivCare’s NEMT operations changed
   dramatically. According to CW1, Simpson began terminating the employment of senior
   employees who knew the business really well.
       ANSWER: Defendants need not respond to the allegations in Paragraph 100 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

100 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 100.

101. CW1 stated that ModivCare’s service quality declined because employees with
   “core competencies” – the core leaders who really knew the NEMT business and how
   to manage that side of the business – were fired or laid off. CW1 added that payors


                                             54


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 55 of 269


    knew and trusted the core leaders, but when they were let go, service quality started
    to decline, complaints from payors increased steadily, until the payors decided to quit
    ModivCare.
       ANSWER: Defendants need not respond to the allegations in Paragraph 101 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

101 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 101.

102. Corroborating CW1, CW3 explained that ModivCare laid off approximately 80% of
   its customer advocate team and implemented major cost reductions for the operations
   team when Simpson arrived at the Company. ModivCare’s customer advocate team
   was responsible for supporting the Company’s transportation providers by answering
   inquiries, documenting and resolving complaints, and supporting scheduling,
   modifying, and canceling reservations.5
       ANSWER: Defendants need not respond to the allegations in Paragraph 102 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph


5
  [Footnote 5 in Complaint] See e.g., FlexJobs, Customer Advocate I ModivCare,
https://www.flexjobs.com/gjw/ModivCare/customer-advocate-i/publicjobs?id=a34c3ad3-
4080-47ef-889c-ae5150395f54 (last accessed Jan. 9, 2026).


                                             55


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 56 of 269


102 and footnote 5 and deny them on that basis. Defendants otherwise deny the

allegations in Paragraph 102 and footnote 5.

103. According to CW3, these staffing cuts eliminated the customer advocate team’s
   capability of working with dispatchers to monitor the NEMT trips live and, as a result,
   ModivCare’s ability to address service issues was diminished. For example, CW3
   described that certain technologies of ModivCare’s software, such as GPS tracking
   and dynamic reassignment (meaning a NEMT trip would be automatically re-booked
   if a driver was unavailable), required dedicated staff advocates because the electronic
   systems were “plagued by bugs” throughout CW3’s tenure and could not fulfill these
   capabilities without human intervention.
       ANSWER: Defendants need not respond to the allegations in Paragraph 103 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

103 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 103.

104. Accordingly, when CW3 heard that the advocate team was eliminated entirely,
   CW3 knew ModivCare did not have the resources to deliver technological
   enhancements that the Company promised to payors. As a result, CW3 stated that
   payors began to consistently express dissatisfaction with ModivCare’s service and
   inquire about no shows and on-time performance issues. CW3 confirmed ModivCare’s
   payors continued to express their dissatisfaction throughout CW3’s tenure.
   Specifically, CW3 recalled that ModivCare’s local Operations teams in Virginia and
   Florida lacked capabilities to address service issues, and that no-shows, on-time
   performance, and overall declining performance were issues in New Jersey.
       ANSWER: Defendants need not respond to the allegations in Paragraph 104 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and


                                             56


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 57 of 269


10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

104 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 104.

105. When asked whether payors refused to pay or delayed payment due to service
   issues, CW1 responded “absolutely” and explained that if service levels were not met,
   ModivCare would bear the cost. CW1 added that, throughout the last year of CW1’s
   employment, ModivCare was failing to meet targets for member satisfaction KPIs,
   including on-time performance, no-show rates, cancellation ratios, and call-center
   responsiveness KPIs.
       ANSWER: Defendants need not respond to the allegations in Paragraph 105 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

105 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 105.

106. CW3 likewise explained that KPIs, such as on time performance, NVA (no vehicle
   available), and complaint volume, were important to ModivCare’s payors. CW3 added
   that ModivCare consistently failed to meet KPIs, including on-time performance and
   NVAs (which caused missed rides), throughout CW3’s tenure.
       ANSWER: Defendants need not respond to the allegations in Paragraph 106 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and


                                             57


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 58 of 269


10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

106 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 106.

107. CW1 recounted three key trends during CW1’s tenure with ModivCare: payors
   cancelling contracts; leadership getting concerned with revenue coming in, because
   contracts were being cancelled; and increased concern with operational performance.
       ANSWER: Defendants need not respond to the allegations in Paragraph 107 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

107 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 107.

108. CW1 explained that, during CW1’s last year with ModivCare, the Company began
   losing NEMT contracts due to service complaints. CW1 added that ModivCare’s
   service levels “were way down” due to poor service quality and high employee
   turnover. Indeed, CW1 stated during this time, payors were “literally cancelling
   contracts because the service, and the people trying to perform the services, kept
   changing so much. The service levels were way down.” CW1 specifically recalled that
   payors, such as UnitedHealthcare and HCSC, cancelled services due to ModivCare’s
   failure to meet member satisfaction KPIs.


                                             58


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 59 of 269


       ANSWER: Defendants need not respond to the allegations in Paragraph 108 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

108 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 108.

109. CW1 also described attending a standing, direct report staff meeting with leaders
   from Operations, Client Services, Process Optimization, Human Resources, Finance,
   Project Management, and Strategy during the summer of 2022 where the rise in
   service complaints and payors’ disappointment over the rise in service complaints
   were being discussed. CW1 explained that meeting attendees were specifically
   discussing members not feeling comfortable with drivers, increased member
   complaints including those about vehicle conditions, member satisfaction concerns,
   and service level agreements.
       ANSWER: Defendants need not respond to the allegations in Paragraph 109 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

109 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 109.

110. During the meeting, according to CW1, Simpson told attendants that ModivCare
   only owned “picking up and dropping” off the member and specifically did not “own the


                                             59


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 60 of 269


   customer experience.” According to CW1, Simpson likened transporting members to
   Amazon’s process for getting packages where they need to go during the meeting. It
   was at this time, according to CW1, that it became clear to CW1 that ModivCare could
   be headed for financial troubles since member experience was critical to the NEMT’s
   business’ success, but was specifically de-prioritized. CW1 described Simpson’s
   directive to ModivCare’s operational leaders as “shocking” and said, “that was the
   moment in time I realized we could be in trouble.”
       ANSWER: Defendants need not respond to the allegations in Paragraph 110 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

110 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

110.

111. CW1 explained that Simpson’s stance that ModivCare was not responsible for
   members’ experience “100%” contributed to the loss of business. CW1 explained that
   running the company became very difficult, as employees with knowledge about
   operations were pushed out, and payors became increasingly dissatisfied. CW1
   added that ModivCare’s abandonment of its core values, such as serving members
   and firing NEMT experts, and the subsequent rise in complaints, all resulted in the
   loss of contracts.
       ANSWER: Defendants need not respond to the allegations in Paragraph 111 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge


                                             60


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 61 of 269


or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

111 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

111.

112. Corroborating CW1, CW2 attributed ModivCare’s damaged payor relationships to
   ModivCare’s new leadership, after former-CEO Daniel Greenleaf departed the
   Company in August 2022, treating the Company as a logistics operation— focusing
   narrowly on financials and prioritizing profit over customer service—despite it being a
   people-driven service business.
       ANSWER: Defendants need not respond to the allegations in Paragraph 112 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants admit that

Daniel Greenleaf was ModivCare’s former CEO. Defendants lack knowledge or

information sufficient to form a belief as to the truth of the CW allegations in Paragraph

112 and deny them on that basis. Except as expressly admitted, Defendants deny the

allegations in Paragraph 112.

113. CW1 also recounted that ModivCare’s service issues resulted in a lot of problems
   with the Big 6, which included UnitedHealthcare, among others. CW1 recalled, during
   the last year of CW1’s tenure, that the payors’ executives would bring concerns to
   ModivCare’s operations team but the operations team was often unprepared to
   respond to their concerns. CW1 said that this “absolutely” contributed to the loss of
   contracts.
       ANSWER: Defendants need not respond to the allegations in Paragraph 113 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed


                                             61


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 62 of 269


in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

113 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

113.

114. When asked whether payors raised these service issues with CW1, CW1 replied
   “all the time.” CW1 also heard about the service issues, including drivers not picking
   members up on time and miscommunications between drivers and members, from the
   operations team, executive teams, and “everyone across the country, weekly.” CW1
   confirmed that the service issues were 100% on Shepard’s and Sampson’s radars.
       ANSWER: Defendants need not respond to the allegations in Paragraph 114 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

114 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

114.

115. CW2 also confirmed that ModivCare quantified its customer service failures,
   explaining that call center performance was tracked. CW2 stated that, beginning
   around 2Q2022 and continuing throughout CW2’s tenure, ModivCare’s poor
   operational performance (such as call center failures) led to payor dissatisfaction and
   monthly liquidated damages of hundreds of thousands of dollars. CW2 stated that
   these service issues were discussed frequently during Monthly Leadership Meetings.
       ANSWER: Defendants need not respond to the allegations in Paragraph 115 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and


                                             62


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 63 of 269


10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

115 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

115.

116. Similarly, CW3 stated ModivCare consistently failed to provide payors with the
   technology and system maintenance offerings that the Company committed to
   delivering in contracts, including ride scheduling, real-time reporting, GPS tracking,
   and dynamic trip reassignment for medical appointments. Indeed, according to CW3,
   by the end of CW3’s tenure at ModivCare, the Company still remained dependent on
   the outdated LogistiCare platform,6 despite spending millions of dollars, over an eight-
   year period, on supposed upgrades.
       ANSWER: Defendants need not respond to the allegations in Paragraph 116 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants admit that on

January 6, 2021, ModivCare changed its name from Providence Service Corporation to

ModivCare, Inc. Defendants lack knowledge or information sufficient to form a belief as

to the truth of the CW allegations in Paragraph 116 and deny them on that basis. Except

as expressly admitted, Defendants deny the allegations in Paragraph 116 and footnote 6.


6
  [Footnote 6 in Complaint] On January 6, 2021, the Company was rebranded from
Providence Service Corporation to ModivCare Inc. and as a part of this rebrand, the
Company’s wholly-owned NEMT subsidiary, LogistiCare Solutions, LLC, was rebranded
to ModivCare Solutions, LLC.


                                             63


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 64 of 269


117. CW3 learned about payors’ complaints that ModivCare was not fulfilling its
   commitments from interactions with ModivCare’s local Operations Managers or
   Regional Vice Presidents when the Company began preparations to respond to a new
   request for proposal (“RFP”). CW3 provided an example where ModivCare promised
   Virginia-based payors certain technological enhancements, such as a new user
   interface for the call center, in connection with a 2018 RFP. According to CW3,
   between 2020 and 2023 while preparing for the next rounds of RFPs, the local
   Operations Manager raised that these 2018 promises remained unfulfilled, and that
   the client had complained about the lack of enhancements previously guaranteed
   during the earlier RFP.
       ANSWER: Defendants need not respond to the allegations in Paragraph 117 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

117 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

117.

118. CW3 also explained that missed appointments and no-shows were significant
   service issues that ModivCare had throughout CW3’s tenure but did not improve on.
   Indeed, CW3 participated in series of communications with Simpson, the President of
   Mobility, during the Spring of 2022 to create a roadmap with technology
   enhancements as part of ModivCare’s RFPs to state MCO clients, specifically in
   response to complaints. Specifically, the roadmap contemplated: GPS tracking with
   real-time trip assignment to reduce no-shows or late arrivals by transportation
   providers; improvements to claims so providers could process payments instantly or
   within 7–14 days; and real- time reporting that would have allowed payors to view on-
   time performance, complaints, and vehicle availability. Yet, despite promising payors
   that the Company had such capabilities in its RFPs during the Class Period, the
   Company never delivered on providing these technological enhancements
   during CW3’s tenure. Indeed, CW3 stated that the technological enhancements in


                                             64


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 65 of 269


   the roadmap never materialized and instead, the Company’s systems had not been
   improved since 2016 and were pieced together with no enhancements.
       ANSWER: Defendants need not respond to the allegations in Paragraph 118 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

118 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

118.

119. As a result, CW3 likewise stated that ModivCare’s poor service delivery, long-
   standing weaknesses in technology, and reliance on an outdated platform caused
   major contracts to be under threat throughout CW3’s tenure. Indeed, between
   November 2022 and the end of CW3’s tenure in September 2023, CW3 held several
   meetings with ModivCare’s leadership, including Defendant Sampson, during which
   CW3 warned leadership that the Company’s contracts were at risk because they were
   failing to keep up with their competitors.
       ANSWER: Defendants need not respond to the allegations in Paragraph 119 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

119 and deny them on that basis. Defendants otherwise deny the allegations in Paragraph

119.


                                             65


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 66 of 269


120. Specifically, CW3 issued such a warning to Defendant Sampson during a week-
   long, in-person Summit in May 2023 at ModivCare’s Denver headquarters, which was
   attended by CW3, Defendant Sampson, the President of ModivCare’s Mobility
   Division Simpson, the Senior VP/Head of Mobility Product Edward Hoffman, and “the
   full c-suite” (the “May 2023 Summit”). During the May 2023 Summit, CW3’s team
   presented competitive analyses that compared ModivCare’s offerings to competitors
   and emphasized long-standing weaknesses in technology, poor service delivery, and
   a disjointed operational model based on the outdated LogistiCare platform.
       ANSWER: Defendants need not respond to the allegations in Paragraph 120 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and

10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5;

see also Dkt. 74 at 2–3. To the extent a response is required, Defendants lack knowledge

or information sufficient to form a belief as to the truth of the CW allegations in Paragraph

120 and deny them on that basis. Defendants otherwise deny the allegations in

Paragraph 120.

121. CW3 explained that Senior VP of Government Affairs Robert Pittman, Senior VP
   of Mobility Edward Hoffman, and Defendant Sampson instructed CW3 to highlight
   capabilities to customers in RFPs that did not exist, including technology platforms the
   company had long promised but never delivered. Indeed, CW3 stated that the
   guidance to CW3’s team was to continue to falsely represent ModivCare’s capabilities
   in RFP even when the technology was not yet implemented or would never be. CW3
   added the RFPs were essentially highlighting vaporware.7
       ANSWER: Defendants need not respond to the allegations in Paragraph 121 to

the extent they are unrelated to the alleged misstatements in ModivCare’s Form 10-K and


7
 [Footnote 7 in Complaint] Vaporware refers to “a computer-related product that has
been widely advertised but has not and may never become available.” See Merriam-
Webster, vaporware, https://www.merriam-webster.com/dictionary/vaporware (last
accessed Jan. 9, 2026).

                                             66


Case No. 1:25-cv-00306-GPG-KAS          Document 79       filed 10/05/26   USDC Colorado
                                       pg 67 of 269


10-Q risk disclosures, which are the only alleged misstatements that the Court addressed

in its August 7, 2026 Order, and Defendants deny them on that basis. See Dkt. 67 at 5

Showing the first 150,000 of 628,868 characters. Full text.